<SEC-DOCUMENT>0000950123-17-008464.txt : 20171010
<SEC-HEADER>0000950123-17-008464.hdr.sgml : 20171009
<ACCEPTANCE-DATETIME>20170911162833
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-17-008464
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20170911
<PUBLIC-REL-DATE>20171010
DATE AS OF CHANGE:		20170919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01713
		FILM NUMBER:		171079257

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted with the Securities and Exchange Commission on September&nbsp;11, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to the Division of Corporation Finance June&nbsp;29, 2017 Announcement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&#147;Draft Registration Statement Processing Procedures Expanded&#148; </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-3828755</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>10421 Pacific Center Court, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT
STYLE="white-space:nowrap">362-6295</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hamza Suria
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AnaptysBio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>10421
Pacific Center Court, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">362-6295</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effie Toshav, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew S. Rossiter, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Robert A. Freedman, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fenwick&nbsp;&amp; West LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>555 California Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94104</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">875-2300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sean M. Clayton, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jonie
I. Kondracki, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Diego, CA 92121</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746; (Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">CALCULATION OF REGISTRATION FEE </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed&nbsp;Maximum<BR>Aggregate Offering<BR>Price(1)(2)</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The proposed maximum aggregate offering price includes the offering price of additional shares that the underwriters have the option to purchase. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#d13239">The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#d13239">SUBJECT
TO COMPLETION, DATED SEPTEMBER&nbsp;11, 2017 </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g71b77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
common stock is listed on The NASDAQ Global Select Market under the symbol &#147;ANAB&#148;. The last reported sale price of our common stock on The NASDAQ Global Select Market on September&nbsp;8, 2017 was $31.84 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares from us at the public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as the term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to
comply with certain reduced public company reporting requirements for this prospectus, the documents incorporated by reference herein and future filings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Investing in our common
stock involves a high degree of risk. See &#147;<A HREF="#toc453477_3">Risk Factors</A>&#148; on page 14 of this prospectus. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Price to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Public</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Underwriting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Discounts and</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proceeds to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Inc.</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission, any state securities commission nor any other regulatory body has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters
expect to deliver the shares on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Credit Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_1">P<SMALL>ROSPECTUS</SMALL>
S<SMALL>UMMARY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_2">T<SMALL>HE</SMALL> O<SMALL>FFERING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_3">R<SMALL>ISK</SMALL> F<SMALL>ACTORS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_4">S<SMALL>PECIAL</SMALL> N<SMALL>OTE</SMALL> R<SMALL>EGARDING</SMALL> F<SMALL>ORWARD
</SMALL><FONT STYLE="white-space:nowrap">-L</FONT><SMALL>OOKING</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_5">M<SMALL>ARKET</SMALL> <SMALL>AND</SMALL> I<SMALL>NDUSTRY</SMALL> D<SMALL>ATA
</SMALL> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_6">U<SMALL>SE</SMALL> <SMALL>OF</SMALL>
P<SMALL>ROCEEDS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_7">D<SMALL>IVIDEND</SMALL> P<SMALL>OLICY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_8">C<SMALL>APITALIZATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_9">D<SMALL>ILUTION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_10">C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL> <SMALL>AND</SMALL> R<SMALL>ELATED
</SMALL> P<SMALL>ARTY</SMALL> T<SMALL>RANSACTIONS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_11">P<SMALL>RINCIPAL</SMALL>
S<SMALL>TOCKHOLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_12">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> C<SMALL>APITAL</SMALL> S<SMALL>TOCK
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_13">M<SMALL>ATERIAL</SMALL> U.S. F<SMALL>EDERAL</SMALL> I<SMALL>NCOME</SMALL> T<SMALL>AX
</SMALL> C<SMALL>ONSIDERATIONS</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-U.S.</FONT> H<SMALL>OLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_14">U<SMALL>NDERWRITING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_15">L<SMALL>EGAL</SMALL> M<SMALL>ATTERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_16">E<SMALL>XPERTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_17">A<SMALL>DDITIONAL</SMALL>
I<SMALL>NFORMATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_18">I<SMALL>NCORPORATION</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> I<SMALL>NFORMATION
</SMALL> <SMALL>BY</SMALL> R<SMALL>EFERENCE</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this prospectus or to which we have referred you. Neither we
nor the underwriters have authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus or in any document incorporated by
reference herein may only be accurate as of the date hereof or thereof, respectively, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock and the information in any free writing prospectus that we may
provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and future growth prospects may have changed since those dates. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are
required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth
under the sections &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case included in, or incorporated by reference into, this prospectus. Unless the context
otherwise requires, we use the terms &#147;AnaptysBio,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to AnaptysBio, Inc. and our subsidiary. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical stage biotechnology company developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody product candidates focused on unmet medical needs in inflammation. We develop our product
candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM,
and replicates this natural process of antibody generation <I>in vitro</I>. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading
biopharmaceutical companies where we retain certain development and commercialization rights in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced
wholly-owned antibody programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically associated with severe inflammatory disorders in humans. ANB020 inhibits the activity of the
<FONT STYLE="white-space:nowrap">interleukin-33</FONT> cytokine, or <FONT STYLE="white-space:nowrap">IL-33,</FONT> for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic
dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of
ANB020, which was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress <FONT STYLE="white-space:nowrap">IL-33</FONT> function for
approximately three months post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We presented these results at the 2017 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma and Immunology 2017
Annual Meeting in March 2017. We have subsequently initiated, under an approved Clinical Trial Authorisation, or CTA, with the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, and completed enrollment of, a Phase 2a trial of ANB020
with 12 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis patients. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the second half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also initiated, under our Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA, a Phase 2a
trial of ANB020 with 20 severe adult peanut allergy patients where efficacy is assessed by measuring the cumulative dose of peanut tolerated in an oral food challenge before and after a single dose of ANB020 or placebo. <FONT
STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the fourth quarter of 2017. We have also received clearance to initiate enrollment, under a CTA with MHRA, of a Phase&nbsp;2a trial of ANB020 in 24 severe adult eosinophilic
asthma patients, where efficacy will be assessed using improvement in Forced Expiratory Volume in One Second after administration of a single dose of ANB020 or placebo. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the
first half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 inhibits the <FONT STYLE="white-space:nowrap">interleukin-36</FONT> receptor, or <FONT
STYLE="white-space:nowrap">IL-36R,</FONT> for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmo-plantar pustular psoriasis, or PPP. We are currently
</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducting, under an approved Clinical Trial Notification, or CTN, a Phase 1 clinical trial in healthy volunteers to assess the safety, pharmacokinetics and pharmacodynamics of ANB019 and
anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial during the fourth quarter of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during
2018. In addition to ANB020 and ANB019, our wholly-owned pipeline includes novel checkpoint receptor agonist antibodies that we believe are applicable for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently
activated, and have demonstrated efficacy in an animal model of graft-versus-host disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our wholly-owned antibody
programs, multiple AnaptysBio-developed antibody programs have been advanced under our collaborations to preclinical and clinical milestones. Our collaborations include an immuno-oncology-focused collaboration with TESARO, Inc. and TESARO
Development, Ltd., or collectively, TESARO, and an inflammation-focused collaboration with Celgene Corporation, or Celgene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our
TESARO collaboration, TESARO has initiated a registration program under an IND with the FDA of an AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antagonist antibody <FONT
STYLE="white-space:nowrap">(TSR-042)</FONT> in metastatic microsatellite high endometrial cancer patients. TESARO has completed dose escalation of an AnaptysBio-generated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-TIM-3</FONT></FONT> antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-022)</FONT> in patients under an IND and has subsequently initiated a combination study of <FONT
STYLE="white-space:nowrap">TSR-022</FONT> and <FONT STYLE="white-space:nowrap">TSR-042.</FONT> In addition, TESARO has initiated a Phase 1 study of an AnaptysBio-generated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> antibody <FONT STYLE="white-space:nowrap">(TSR-033),</FONT> and TESARO has initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies
for an&nbsp;AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/LAG-3</FONT></FONT> bispecific antibody, which has exhibited similar levels of <FONT STYLE="white-space:nowrap">T-cell</FONT> activation&nbsp;in
vitro&nbsp;as a combination of <FONT STYLE="white-space:nowrap">TSR-042</FONT> and <FONT STYLE="white-space:nowrap">TSR-033.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
our collaboration with Celgene, Celgene is advancing two AnaptysBio-generated anti-inflammatory antibody programs. One of these programs is an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> agonist antibody
<FONT STYLE="white-space:nowrap">(CC-90006)</FONT> currently in a Phase 1 trial for psoriasis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through June&nbsp;30, 2017, we have
received $73.6&nbsp;million in <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding from our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is led by
a strong management team with deep experience in antibody discovery and development, collaborations, operations and corporate finance. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to
treat severe diseases with unmet medical need. The following table summarizes certain key information about our wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g71e42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product candidates are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANB020</B> is a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody that inhibits the activity of <FONT STYLE="white-space:nowrap">IL-33,</FONT> a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine
that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. <FONT STYLE="white-space:nowrap">IL-33</FONT> directly mediates release of disease-associated cytokines, which
recruit <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cells that mediate atopic disease. Because ANB020 inhibits <FONT STYLE="white-space:nowrap">IL-33</FONT> function, and acts upstream broadly across the key cell types and cytokines
involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines responsible for atopic diseases. The role of
<FONT STYLE="white-space:nowrap">IL-33</FONT> signaling in asthma has been recently genetically validated through human studies published in the medical literature. We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia. We
believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was
sufficient to suppress <FONT STYLE="white-space:nowrap">IL-33</FONT> function for approximately three months post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We presented these results at the 2017 American
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma and Immunology 2017 Annual Meeting in March 2017. We have subsequently initiated, under an approved CTA with
MHRA, and completed enrollment of, a Phase 2a trial of ANB020 with 12 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis patients, for which
<FONT STYLE="white-space:nowrap">top-line</FONT> data is anticipated during the second half of 2017. We have also initiated, under our IND a Phase 2a trial of ANB020 in the United States with 20 severe adult peanut allergy patients where efficacy
will be assessed by measuring the cumulative dose of peanut tolerated in an oral food challenge before and after a single dose of ANB020 or placebo. We anticipate <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial will be
available during the fourth quarter of 2017. We have also received clearance to initiate enrollment, under a CTA with the MHRA, of a Phase 2a trial of ANB020 with 24 severe adult eosinophilic asthma patients, where efficacy will be assessed using
improvement in Forced Expiratory Volume in One Second after administration of a single dose of ANB020 or placebo. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the first half of 2018. Based on our analysis of publicly
available data sources and interviews with physicians and key opinion leaders in the field of atopic dermatitis, we estimate approximately 1.4&nbsp;million adults in the United States are affected by atopic dermatitis, of which approximately 280,000
are diagnosed with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> form of this disease, of which 98,000 are believed to be suitable for treatment with systemic biological therapies. Peanut
allergy is the most common cause of food-induced allergy in the United States. Based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the food allergy field, we estimate approximately
1.7&nbsp;million adults are affected by peanut allergy, of which approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological
therapies in the United States. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders focused on asthma, that asthma affects approximately 19.0&nbsp;million individuals, of which
approximately 1.1 million have severe disease that cannot be controlled by standard-of-care therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB019</B> is an antibody that inhibits the function of <FONT STYLE="white-space:nowrap">IL-36R,</FONT> which we are initially developing as a potential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapy for GPP and PPP patients. GPP is a life-threatening, rare, systemic inflammatory disorder that, based on our analysis of publicly available data
sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no approved therapies. Studies have shown that GPP can be associated in some patients with
mutations that lead to abnormally high signaling through the <FONT STYLE="white-space:nowrap">IL-36R,</FONT> which we believe can be addressed by treatment with ANB019 irrespective of whether a GPP patient has a mutated <FONT
STYLE="white-space:nowrap">IL-36R</FONT> signaling pathway. PPP is a <FONT STYLE="white-space:nowrap">non-fatal</FONT> form of pustular psoriasis that we estimate affects approximately 150,000 patients in the United States alone. PPP is believed to
be caused by increased systemic levels of <FONT STYLE="white-space:nowrap">interleukin-36</FONT> resulting in inflammatory pustules on the hands and feet of patients that cause significant inability to stand, walk or do manual work, which we believe
can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic antibody targeting <FONT STYLE="white-space:nowrap">IL-36R</FONT> in development. We are currently conducting, under an approved CTN, a Phase 1 clinical
trial in healthy volunteers to assess the safety, pharmacokinetics and pharmacodynamics of ANB019 and anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial during the fourth quarter of 2017. We subsequently plan
to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018. We plan to seek FDA Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant Orphan Drug Designation to a drug intended to
treat a disease or condition that generally affects fewer than 200,000 individuals in the United States. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Checkpoint receptor agonist</B> antibodies are being developed by AnaptysBio to multiple different immune
checkpoint receptors for the treatment of certain autoimmune diseases where we believe checkpoint receptor function is insufficiently activated. Known human immune checkpoint receptors
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
include <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">LAG-3,</FONT> BTLA and TIGIT. We have discovered certain
checkpoint receptor agonist antibodies that have demonstrated efficacy in a rodent model of graft-versus-host disease. We anticipate that, subsequent to regulatory clearance, one of our wholly-owned checkpoint receptor antibodies will initiate human
testing during 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Advantages of Our SHM Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to developing novel therapeutic antibody product candidates is based upon SHM, a critical, endogenous process that generates the
essential antibody diversity required to develop a natural immune response to pathogens. Our proprietary antibody generation platform is designed to replicate the natural process of SHM <I>in vitro.</I> Competing antibody discovery technologies
include mouse immunization methodologies, microbial antibody display and human <FONT STYLE="white-space:nowrap">B-cell</FONT> screening. We believe our SHM platform overcomes several key limitations associated with these competing technologies and
has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology has enabled us to generate therapeutic-grade antibodies and subsequently advance preclinical manufacturing and toxicology studies to the filing of an IND or foreign equivalent,
typically in approximately 2.5 years. We believe this timeline is significantly shorter than conventional antibody discovery approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By using mammalian cell display to generate our therapeutic antibodies, we believe our platform mitigates risks associated with antibody expression, formulation and stability during the
antibody generation process. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Collaborations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $73.6&nbsp;million in payments
through June&nbsp;30, 2017. Multiple antibodies, generated by us prior to or during a strategic collaboration, are currently being advanced through development by our collaborators. Our collaborations with TESARO and Celgene are described below:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our
immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM platform consisting of the following antibody product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-042):&nbsp;Registration</FONT> program initiated for
metastatic microsatellite instability high <FONT STYLE="white-space:nowrap">(MSI-H)</FONT> endometrial cancer; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-TIM-3</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-022):&nbsp;Dose</FONT> escalation completed in Phase 1,
combination trial with <FONT STYLE="white-space:nowrap">TSR-042</FONT> has been initiated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-LAG-3</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-033):&nbsp;Phase</FONT> 1 trial initiated, and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1/LAG-3</FONT></FONT></FONT> Bispecific Antagonist Antibody:&nbsp;lead candidate identified, <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies <FONT STYLE="white-space:nowrap">on-going.</FONT> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the option to obtain
worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis by our
delivery of antibodies meeting certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> parameters pertaining to each target under collaboration. Celgene is currently advancing two AnaptysBio-generated anti-inflammatory antibody programs, where
one of these programs is an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> agonist antibody <FONT STYLE="white-space:nowrap">(CC-90006)</FONT> currently in a Phase 1 trial for psoriasis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate the following
milestones relating to wholly-owned pipeline programs to be attained during the remainder of 2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #0d8dd3; padding-left:8pt"><B>Program</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #0d8dd3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #0d8dd3"><B>Milestone</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #0d8dd3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #0d8dd3"><B>Anticipated&nbsp;Timing</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" BGCOLOR="#e6f3fa"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">ANB020&nbsp;(Anti-IL-33)</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Atopic Dermatitis Phase 2a Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">H2&nbsp;2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Peanut Allergy Phase 2a Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">Q4 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Eosinophilic&nbsp;Asthma&nbsp;Phase&nbsp;2a&nbsp;Top-Line&nbsp;Data</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H1&nbsp;2018</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ANB019&nbsp;
(anti-IL-36R)</FONT></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Healthy Volunteer Phase 1 Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">Q4 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">GPP Phase 2 Initiation</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PPP Phase 2 Initiation</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2018</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading antibody development company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our
technology platform to emerging biological targets. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advancing our wholly-owned lead product candidates to clinical milestones.</B> We are working to demonstrate
the safety and efficacy of our wholly-owned pipeline programs, and have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia, which we believe has demonstrated favorable safety and <I>ex vivo</I> pharmacodynamic properties. We are
conducting multiple Phase 2a trials of ANB020: top-line results from a Phase 2a trial in patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis are
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
anticipated during the second half of 2017; <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 2a trial in patients with severe adult peanut allergy are anticipated in the fourth
quarter of 2017; and <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 2a trial in patients with severe adult eosinophilic asthma are anticipated during the first half of 2018. We are currently conducting, under an approved CTN, a
Phase 1 clinical trial in healthy volunteers to assess the safety, pharmacokinetics and pharmacodynamics of ANB019 and anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial during the fourth quarter of 2017. We
subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform.</B> Using our proprietary SHM antibody generation platform, we are able to rapidly develop novel
antibodies against biological emerging targets. Our goal is to continue expanding our wholly-owned new therapeutic antibody program pipeline by innovating one or more novel pipeline antibodies each year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating
biological breakthroughs into <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies. Our approach includes translational biology assessments, such as human genetics, <I>ex vivo</I>
tissue pathology and target expression patterns, to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs
for rapid initial efficacy assessment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets.</B> We intend to retain ownership and control of our pipeline programs to key preclinical and clinical data inflection points. We may build sales and
marketing capabilities in the United States with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development
and commercialization. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Affecting Us </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks and uncertainties, including those highlighted and incorporated by reference in the section
titled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. If we or our collaborators are unable to complete development of
or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may demonstrate limited efficacy
or reveal significant adverse events, toxicities or other side effects and may result in an efficacy or safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to
commercialize and generate revenue from our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have only recently commenced clinical development of ANB019 and ANB020 and have no other history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the
prospects for our future viability. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if
these collaborations are not successful, our business could be adversely affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of
our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or
profit from product sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product
candidates or develop new product candidates. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in November 2005. Our principal executive offices are located at 10421 Pacific
Center Court, Suite 200, San Diego, California 92121, and our telephone number is (858) <FONT STYLE="white-space:nowrap">362-6295.</FONT> Our website address is www.anaptysbio.com. The information contained on, or that can be accessed through, our
website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mark &#147;AnaptysBio&#148; is our common law trademark. All other service marks, trademarks and trade names appearing in this prospectus
are the property of their respective owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, enacted in April 2012. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These
provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth
anniversary of the closing of our initial public offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion
or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a
part and the documents incorporated herein by reference and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging growth company
can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we are subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares to be offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock to be outstanding immediately after this offering </P></TD>
<TD><BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in
full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their
option to purchase additional shares in full), based upon the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds that we receive in this offering to fund research and development activities for our clinical development programs, our ongoing preclinical, discovery and research programs, and for
working capital and other general corporate purposes. We may use a portion of the proceeds to acquire other complementary businesses or technologies, although we have no present commitments or agreements to do so. See &#147;Use of Proceeds&#148; for
a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ANAB&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 20,289,907
shares of our common stock outstanding as of June&nbsp;30, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">55,715 shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $21.61 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans as of June&nbsp;30, 2017, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our
2017 Equity Incentive Plan and (b) 218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual
increases in the number of shares reserved under the plans each year, as more fully described in note 8 of the notes to our unaudited consolidated financial statements included in our Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all
information in this prospectus assumes no exercise of outstanding options or warrants and no exercise of the underwriters&#146; option to purchase additional shares. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary consolidated statements of operations data presented below for the years ended December&nbsp;31, 2014, 2015 and 2016 are derived
from our audited financial statements incorporated by reference into this prospectus. The selected consolidated statements of operations data for the six months ended June&nbsp;30, 2016 and 2017 and the summary consolidated balance sheet data as of
June&nbsp;30, 2017 have been derived from our unaudited consolidated financial statements incorporated by reference into this prospectus. Our unaudited consolidated financial statements have been prepared on the same basis as our audited financial
statements and, in the opinion of management, reflect all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of those unaudited consolidated financial statements. The following summary consolidated
financial data should be read with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes incorporated by reference into this prospectus. Our historical
results are not necessarily indicative of the results that may be expected in any future period. The summary financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial
statements and related notes incorporated by reference into this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on available for sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;2 to our audited consolidated financial statements incorporated by reference in this prospectus for an explanation of the method used to calculate basic and diluted net income (loss) per common share and
the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>June&nbsp;30, 2017<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As<BR>Adjusted(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted balance sheet data give effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock by us in this offering,
based on an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, would increase (decrease) each of our as adjusted cash, cash equivalents, short-term investments, total assets and total
stockholders&#146; equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us remains the same and after deducting the estimated underwriting discounts and commissions.
Similarly, each increase (decrease) of one million shares in the number of shares offered by us would increase (decrease) each of our as adjusted cash, cash equivalents, short-term investments, total assets and total stockholders&#146; equity by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed public offering price remains the same and after deducting the estimated underwriting discounts and commissions. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you
should carefully consider the risks described in Part II, Item 1A of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2017 and Part I, Item&nbsp;1A of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2016, together with all of the other information contained in or incorporated by reference into this prospectus. We cannot assure you that any of the events discussed herein
or therein will not occur. These events could have a material and adverse impact on our business, results of operations, financial condition and cash flows. If that were to happen, the trading price of our common stock could decline, and you could
lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase
the value of your investment. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion to use the net proceeds from this offering, including for any
of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity to influence our decisions on how
to use the proceeds, and we may not apply the net proceeds of this offering in ways that increase the value of your investment. Because of the number and variability of factors that will determine our use of the net proceeds from this offering,
their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we intend to invest the net proceeds from this offering in
marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. These investments may not yield a favorable
return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will suffer immediate and substantial dilution in the net tangible book value of our common stock you purchase in this offering. Assuming a
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, purchasers of common stock in this offering will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share in net tangible book value of our common stock. In the past, we issued options, warrants and other securities to acquire common stock at prices below the public offering price. To the extent these outstanding securities are ultimately
exercised, or we issue equity or convertible debt securities in the future at a price less than the public offering price, investors purchasing common stock in this offering will sustain further dilution. See &#147;Dilution&#148; for a more detailed
description of the dilution to new investors in the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into this prospectus, including the sections entitled &#147;Prospectus
Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business&#148;, contains forward-looking statements. The words
&#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan&#148;
&#147;expect,&#148; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus and the documents incorporated by reference into this prospectus include, among other
things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize antibodies, including our lead product candidates ANB020 for patients with severe allergic and atopic diseases and ANB019 for patients with GPP and PPP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood that the clinical data generated in any study we are performing or plan to perform in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction will be subsequently accepted by the FDA and its
foreign regulatory authorities outside of the jurisdiction where the study was being performed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and ability of our collaborators to develop and commercialize our partnered product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential benefits and advantages of our product candidates and approaches versus those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline and retaining rights
to strategic products in key commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for ANB020 and ANB019 and our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States, the United Kingdom, Australia and other foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing therapies that are or may become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described or incorporated by
reference in &#147;Risk Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor
can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these
risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.
We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the documents incorporated by reference into this prospectus and the documents that we reference in this
prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be
materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_5"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our industry and the markets
in which we operate, including our general expectations and market position, market opportunity, and market size, is based on information from various sources and on assumptions that we have made that are based on those data and other similar
sources and on our knowledge of the markets for our products. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market
opportunity and market size information included in or incorporated by reference into this prospectus is generally reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and
the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148; and in the documents incorporated by
reference into this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale
price of our common stock on The NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional
shares in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed public offering price would increase (decrease) the net proceeds to us from
this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, remains the same, and after deducting the estimated underwriting discounts and commissions. Similarly, each increase or decrease
of one million in the number of shares of common stock offered by us would increase (decrease) the net proceeds that we receive from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed public offering
price remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents and investments,
to fund research and development activities for our clinical development programs, including, but not limited to, our ongoing and planned clinical trials for ANB020 and ANB019, including related manufacturing costs, and our ongoing preclinical,
discovery and research programs, and for working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our planned use of the net
proceeds, we estimate such funds, together with our existing cash, cash equivalents and investments, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 24 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of
the date of this prospectus, we cannot predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. We may use a portion of the net proceeds for the acquisition
of, or investment in, technologies, solutions or businesses that complement our business, although we have no present commitments or agreements to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our clinical expenditures and the extent of clinical development may vary significantly depending on numerous
factors, including the status, results and timing of our current and planned preclinical studies and clinical trials, product approval process with the FDA and other regulatory agencies, our current collaborations and any new collaborations we may
enter into with third parties and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected net proceeds of this offering will not be sufficient for us to fund any of our product candidates through regulatory approval,
and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we intend to invest the net proceeds from this offering in short term and long-term, investment-grade
interest-bearing securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET PRICE OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has been listed on The NASDAQ Global Select Market under the symbol &#147;ANAB&#148; since January&nbsp;25, 2017. Prior to
that date, there was no public trading market for our common stock. The following table sets forth for the periods indicated the high and low sale prices per share of our common stock as reported on The NASDAQ Global Select Market for the periods
indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fiscal Year 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter (beginning January&nbsp;25, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter (through September&nbsp;8, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;8, 2017, the last reported sale price of our common stock on The NASDAQ Global Select Market
was $31.84 per share. As of June&nbsp;30, 2017, we had 95 registered holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose
shares are held in street name by brokers and other nominees. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend
on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. In addition, under the terms of our current credit facility, we are prohibited from
paying cash dividends without the consent of Silicon Valley Bank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of June&nbsp;30, 2017 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an as adjusted basis, giving effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock by us in this offering, based on an assumed public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by
us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual
public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited and unaudited consolidated financial statements and related notes incorporated by reference into this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2017<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and par value data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;Adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding,
actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 500,000,000 shares authorized, 20,289,907 shares issued and
outstanding, actual; 500,000,000 shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">(59<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(69,083</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, would increase (decrease) each of our as adjusted cash, cash equivalents and short-term investments, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us remains the same
and after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of one million shares in the number of shares offered by us would increase (decrease) each of our as adjusted cash, cash equivalents and
short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the
assumed offering price remains the same and after deducting the estimated underwriting discounts and commissions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
number of shares of our common stock to be outstanding after this offering is based on 20,289,907 shares of our common stock outstanding as of June&nbsp;30, 2017, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">55,715 shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $21.61 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our 2017 Equity Incentive
Plan and (b) 218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the number of
shares reserved under the plans each year, as more fully described in the section &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended June&nbsp;30, 2017 and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted to the extent of the difference between the amount per share paid by
purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, our net tangible book value was approximately $109.2&nbsp;million, or $5.38 per share of common stock. Our net
tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of June&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale in this offering of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock at an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us, our net tangible book value as of June&nbsp;30, 2017 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This represents an
immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors
purchasing shares in this offering, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the last reported sale price of our common stock on The NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, would increase (decrease) our net tangible book value, as adjusted to give effect to this offering, by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution in as adjusted net tangible book value per share to new investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase of one
million shares in the number of shares offered by us in this offering would increase our as adjusted net tangible book value per share, and decrease the dilution per share to investors in this offering, by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Each decrease of one million shares in the number of shares offered by us would decrease our as adjusted net tangible book value per share, and increase the dilution per share to investors
in this offering, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to
purchase additional shares, the net tangible book value per share of our common stock after giving effect to this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in net tangible book value per share to
investors in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock
to be outstanding after this offering is based on 20,289,907 shares of our common stock outstanding as of June&nbsp;30, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">55,715 shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $21.61 per share; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our 2017 Equity Incentive
Plan and (b) 218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the number of
shares reserved under the plans each year, as more fully described in the section &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended June&nbsp;30, 2017 and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that options or warrants outstanding as of June&nbsp;30, 2017 have been or may be exercised, or we issue new options or
warrants, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds
for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_10"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe below transactions and series of similar transactions since January&nbsp;1, 2014 to which we were a party or will be a party, in
which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions
or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under the section entitled &#147;Executive Compensation&#148; in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equity Financings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 474,001 shares of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock
at a purchase price of $4.55 per share, in exchange for the cancellation of secured convertible promissory notes originally issued in July 2013, which as of April 2014 had an aggregate principal and unpaid interest of $2.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock issued to our executive
officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR>Series <FONT STYLE="white-space:nowrap">C-1</FONT><BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">351,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier Healthcare and may be deemed to
have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a former member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership
of or pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock converted automatically into one share of our
common stock upon the closing of our initial public offering. The purchasers of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock are entitled to specified registration rights, as described under &#147;Description of
Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Series D Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we sold an aggregate of 5,490,973 shares of our Series D convertible preferred stock at a purchase price of $7.42 per share, for
an aggregate cash purchase price of $40.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series D convertible preferred stock purchased
by our executive officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR>Series D<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,503,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBM Healthcare Investments (Cayman) Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P., both affiliates of Frazier Healthcare. Dr.&nbsp;Topper, a member of our Board of
Directors, is a General Partner of Frazier Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a former member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership
of or pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hoffman is our former Chief Financial Officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Londei is our Chief Medical Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series D convertible
preferred stock converted automatically into one share of our common stock upon the closing of our initial public offering. The purchasers of our Series D convertible preferred stock are entitled to specified registration rights, as described below
under &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Participation in our Initial Public Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our principal stockholders and their affiliated entities, including stockholders affiliated with certain of our directors,
purchased an aggregate of 1,316,666 shares of our common stock in our initial public offering on January&nbsp;31, 2017 at the initial public offering price of $15.00 per share. The following table summarizes common stock purchased by members of our
board of directors and entities who held more than 5% of our outstanding capital stock at the time of the purchase: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>Purchased</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D.,FRS(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,749,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 414,373 shares purchased by Biotechnology Value Fund, L.P., 269,019 shares purchased by Biotechnology Value Fund II, L.P., 74,064 shares purchased by Biotechnology Value Trading Fund OS, L.P. and 92,544
shares purchased by MSI BVF SPV LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 311,291 shares purchased by Frazier Healthcare VII, L.P and 88,709 shares purchased by Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. Dr.&nbsp;Topper, a member of our Board of
Directors, is a General Partner of Frazier Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated Investors&#146;
Rights Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investors&#146; rights agreement with certain holders of our
convertible preferred stock, including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares. For a description of these registration rights, see
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements, our
restated certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our restated bylaws also require us to advance expenses
incurred by our directors and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted a written related person transactions policy that our executive officers, directors, nominees for election as a director,
beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the
review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. The policy provides that any
request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in which the amount
involved exceeds $120,000 will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed
relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related
person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_11"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at August&nbsp;31, 2017, and
as adjusted to reflect the sale of common stock in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect
to all shares of common stock that they beneficially owned, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage
ownership is based on 20,469,570 shares of common stock outstanding as of August&nbsp;31, 2017. For purposes of the table below, we have assumed
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be issued by us in this public offering. In computing the number of shares of common stock beneficially owned
by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60 days of
August&nbsp;31, 2017. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o
AnaptysBio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, California 92121. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial Ownership<BR>Prior to this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial&nbsp;Ownership<BR>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo Holdings A/S<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,904,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Schmid<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Anthony Ware, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (ten persons)<SUP
STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,147,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on Schedule <FONT STYLE="white-space:nowrap">13-D</FONT> filed by Frazier Healthcare V, L.P. on February&nbsp;10, 2017. Consists of (a) 2,345,612 shares of common stock held directly by Frazier Healthcare V, L.P.,
(b) 1,045,031 shares of common stock held directly by Frazier Healthcare VII, L.P., (c) 297,804 shares of common stock held directly by Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P.. The general partner of Frazier Healthcare
V, L.P. is FHM V, L.P., a Delaware limited partnership. The general partner of FHM V, L.P. is FHM V, LLC, a Delaware limited liability company. The general partner of Frazier Healthcare VII, L.P. and Frazier Healthcare
<FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. is FHM VII, L.P., a Delaware limited partnership. The general partner of FHM VII, L.P. is FHM VII, LLC, a Delaware limited liability company. Dr.&nbsp;Topper, a member of our Board of Directors,
Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are members of FHM V, LLC and FHM VII, LLC and may be deemed to share voting and investment power with respect to the shares held by FHM V, LLC and FHM VII, LLC. The address of Frazier
Healthcare is 601 Union, Two Union Square, Suite 3200, Seattle WA 98101. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on Form 4 filed by Novo Holdings A/S on August&nbsp;21, 2017. Consists of (a) 1,936,604 shares of common stock held directly by Novo Holdings A/S. The board of directors of Novo A/S, which is currently comprised
of Sten Scheibye, G&ocirc;ran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared voting and investment power with respect to these shares and may exercise such control only with the support of a majority of the board. As such,
no individual member of the board is deemed to hold any beneficiary ownership in these shares. The address of Novo A/S is Tuborg Havnevej 19, 2900 Hellerup, Denmark. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,282,485 shares of common stock held directly by Alloy Ventures 2005, L.P. The general partner of Alloy Ventures 2005, L.P. is Alloy Ventures 2005, LLC. The managing members of Alloy Ventures 2005, LLC are
Craig Taylor, Doug Kelly John Shoch, Dan Rubin and Tony Di Bona. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Based on Schedule <FONT STYLE="white-space:nowrap">13-G</FONT> filed by Biotechnology Value Fund L.P. on January&nbsp;26, 2017. Consists of (a) 907,116 shares of common stock held directly by Biotechnology Value Fund,
L.P., (b) 551,019 shares of common stock directly by Biotechnology Value Fund II, L.P., (c) 74,064 shares of common stock held directly by Trading Fund OS and (d) 372,401 shares of common stock held directly in the Partners Managed Accounts.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 4,998 shares of common stock held directly by Mr.&nbsp;Suria and (b) 557,332 shares of common stock issuable to Mr.&nbsp;Suria upon the exercise of stock options that are exercisable within 60 days of
August&nbsp;31, 2017, of which 102,499 shares were unvested but were early exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 2,020 shares of common stock held directly by Dr.&nbsp;Londei and (b) 210,918 shares of common stock issuable to Dr.&nbsp;Londei upon the exercise of stock options that are exercisable within 60 days of
August&nbsp;31, 2017, of which 40,241 shares were unvested but were early exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Moyle resigned as our Chief Scientific Officer effective July&nbsp;21, 2017. Consists of (a) 30,000 shares of common stock held directly by Mr.&nbsp;Moyle and (b) 19,411 shares of common stock issuable to
Mr.&nbsp;Moyle upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 64,296 shares of common stock held directly by Dr.&nbsp;Gallagher and (b) 97,722 shares of common stock issuable to Dr.&nbsp;Gallagher upon the exercise of stock options that are exercisable within 60
days of August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 287,623 shares of common stock held directly by Dr.&nbsp;Lydon, (b) 16,483 shares of common stock issuable upon the exercise of a warrant held directly by Dr.&nbsp;Lydon and (c) 31,012 shares of common
stock issuable to Dr.&nbsp;Lydon upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 2,134 shares were unvested but were early exercisable, as of 60 days after August&nbsp;31, 2017.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Represents 51,156 shares of common stock issuable to Mr.&nbsp;Renton upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 11,652 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337 shares of common stock issuable to Mr.&nbsp;Schmid upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 12,275 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337 shares of common stock issuable to Mr.&nbsp;Schoeneck upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 15,288 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,588 shares of common stock issuable to Mr.&nbsp;Ware upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares beneficially owned by our executive officers and directors. Consists of (a) 4,077,384 shares of common stock, (b) 16,483 shares of common stock issuable upon the exercise of warrants and (b) 1,053,813
shares of common stock issuable upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 184,089 shares were unvested but early exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above table does not include Dominic G. Piscitelli, who commenced his employment with us as our Chief Financial Officer in January 2017.
As of August&nbsp;31, 2017, Mr.&nbsp;Piscitelli was granted options to purchase 245,241 shares of our common stock, none of which are exercisable within 60 days of August&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_12"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 500,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated
preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete
description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, there were 20,289,907 shares of our common stock issued, held by approximately 95 stockholders of record, and
no shares of our preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional shares of our capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dividend
Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common
stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See
&#147;Dividend Policy&#148; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation. Accordingly, pursuant to our restated certificate of incorporation, holders of a majority of the shares of our common stock can elect all of
our directors. Our restated certificate of incorporation establishes a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with
the other classes continuing for the remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>No Preemptive or Similar Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Right to Receive Liquidation Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of
and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to
establish from time to time the number of shares to be included in each series and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by
our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing
flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our
common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2017, we had outstanding warrants to purchase an aggregate of 198,009 shares of our common stock, with an exercise price of $4.55 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Options </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2017, we had outstanding options to purchase an aggregate 2,643,180 shares of our common stock, with a weighted-average exercise price of $10.62. Subsequent to June&nbsp;30, 2017, we granted stock options to purchase 55,715 shares of
common stock, with a weighted-average exercise price of $21.61 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our Amended and Restated Investor Rights Agreement, the holders of approximately 9,240,026 shares of our common stock
are entitled to rights with respect to the registration of these shares under the Securities Act, as described below. We refer to these shares collectively as registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Demand Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any point, the holders of at least a majority of the then-outstanding registrable securities may make a written request to us for the
registration of any of the registrable securities under the Securities Act. Within 30 days of such request, we are obligated to provide written notice of such request to all stockholders to file a registration statement under the Securities Act
covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration
statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total
period of not more than 60 days if our board of directors determines in its good faith judgment that it would be seriously detrimental to us and our stockholders for such registration statement to be effected at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any holder of then-outstanding registrable securities can request that we register all or part of their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and if the aggregate price to the public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the shares offered is at least $2,000,000. The stockholders may only require us to effect two registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in a <FONT
STYLE="white-space:nowrap">12-month</FONT> period. We may postpone taking action with respect to such filing once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total cumulative period of not more than 90 days if our board
of directors determines in its good faith judgment that the filing would be materially detrimental to us and our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Piggyback Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of registrable securities were entitled to, and the necessary percentage of holders waived, their
rights to notice of this offering and to include their registrable securities in this offering. If we register any of our securities for public sale in another offering, holders of registrable securities will have the right to include their shares
in the registration statement. However, this right does not apply to a registration relating to employee benefit plans, a registration relating to a corporate reorganization or a registration of only common stock issuable upon conversion of debt
securities that are also being registered. We have the right to terminate any registration we have initiated before the effective date of such registration, whether or not any holder has elected to include registrable securities in such
registration. The underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if they determine in good faith that marketing factors require limitation, in which case the number of shares
to be registered will be apportioned pro rata among these holders, according to the total amount of securities entitled to be included by each holder, or in a manner mutually agreed upon by the holders. However, in any underwriting not in connection
with an initial public offering, the number of shares to be registered by these holders cannot be reduced below 30% of the total shares covered by the registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expenses of Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, other than underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expiration of Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights described above will expire, with respect to any particular holder of these rights, on the earlier of the fifth
anniversary of the closing of our initial public offering, a merger, consolidation, sale or disposition of our company or a sale by a holder of equity securities representing at least a majority of the voting power of our company, or when that
holder can sell all of its registrable securities in a three-month period without restriction under Rule 144 of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring
or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control
of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to
acquire us because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the
outstanding voting stock owned by the interested stockholder, (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine
confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in
a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also
discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restated
Certificate of Incorporation and Restated Bylaw Provisions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws include
a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board of Directors Vacancies.</I> Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the
number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of
directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Classified Board.</I> Our restated certificate of incorporation and restated bylaws provide that our board is classified into three classes of directors, each with staggered three-year terms. A third party may be
discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders.</I> Our restated certificate of incorporation provides
that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated
bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of
directors, the chairman of our board </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of
stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might
preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Cumulative Voting.</I> The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#146;s certificate of
incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Directors Removed Only for Cause.</I> Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Amendment of Charter Provisions.</I> Any amendment of the above provisions in our restated certificate of incorporation would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT>
of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and
preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt
to obtain control of us by merger, tender offer, proxy contest or other means. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Choice of Forum.</I> Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf;
any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim
against us that is governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer and Trust Company, LLC. The transfer agent&#146;s address is
6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) <FONT STYLE="white-space:nowrap">937-5449.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_13"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section summarizes the material U.S. federal income tax considerations
relating to the acquisition, ownership and disposition of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holders&#148; (as defined below). This summary does not provide a complete analysis of all
potential U.S. federal income tax considerations relating thereto. The information provided below is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative
rulings and judicial decisions currently in effect. These authorities may change at any time, possibly retroactively, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax
considerations of owning or disposing of our common stock could differ from those described below. As a result, we cannot assure you that the tax consequences described in this discussion will not be challenged by the IRS or will be sustained by a
court if challenged by the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the tax considerations arising under the laws of any <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> state or local jurisdiction, or under U.S. federal gift and estate tax laws, except to the limited extent provided below. In addition, this discussion does not address tax considerations applicable to an
investor&#146;s particular circumstances or to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or other entities treated as partnerships or pass-through entities for U.S. federal tax purposes (or investors in such entities); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the Medicare contribution tax on net investment income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations or passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our common stock as compensation for services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership or entity classified as a partnership or other pass-through entity for U.S. federal income tax purposes is a
beneficial owner of our common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Accordingly, this
summary does not address tax considerations applicable to partnerships that hold our common stock, and partners in such partnerships should consult their tax advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS
REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; is any beneficial owner of our common
stock, other than a partnership, that is not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state therein or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if it (i)&nbsp;is subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;has a valid election in effect
under the applicable Treasury regulations to be treated as a U.S. person; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. income tax regardless of source. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> citizen who is an individual, you may, in some cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the United States for at least 31 days in the
calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. Generally, for this purpose, all the days present in the current year, <FONT STYLE="white-space:nowrap">one-third</FONT> of the
days present in the immediately preceding year, and <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the days present in the second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens.
Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the ownership or disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dividends </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
expect to declare or make any distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied
against and reduces, but not below zero, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in shares of our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of our
common stock. See &#147;&#151;Sale of Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any dividend paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
on our common stock that is not effectively connected with a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The
withholding tax might apply at a reduced rate, however, under the terms of an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence. You should consult your
tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must certify its
entitlement to treaty benefits. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally can meet this certification requirement by providing a Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or any successor of such forms) or appropriate substitute form to us or our paying agent. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the stock through a financial
institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to the agent. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder&#146;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S.
federal withholding tax under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively connected with a U.S. trade or business
conducted by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, and if required by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, are
attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, are not subject to U.S. withholding tax. To obtain this exemption, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must provide us or our paying agent with an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> properly certifying such exemption. Such effectively connected dividends, although not
subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition to being taxed at graduated tax rates, dividends received by corporate
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that are effectively connected with a U.S. trade or business of the corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may also be subject to a branch profits tax at a rate of
30% or such lower rate as may be specified by an applicable tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See also the section below titled &#147;&#151;Foreign Account Tax
Compliance Act&#148; for additional withholding rules that may apply to dividends paid to certain foreign financial institutions or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sale of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding Backup Withholding and Information Reporting and the Foreign Account Tax Compliance Act, <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain (i)&nbsp;is effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between
the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States (in which case the special rules described below apply); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock,
and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the
individual is not considered a resident of the United States); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FIRPTA rules may apply to a sale, exchange or other disposition of our common stock if we are, or were within the shorter of the five-year
period preceding the disposition and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, a &#147;U.S. real property holding corporation,&#148; or USRPHC. In general, we would be a USRPHC if interests in U.S. real
estate comprised at least half of the value of our business assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, gain realized by a Non U.S. Holder on a disposition of our
common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the Non U.S. Holder owned, directly, indirectly or constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the five
year period preceding the disposition or (ii)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an established securities market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any gain from the sale, exchange or other disposition of our common stock, (i)&nbsp;is effectively connected with a U.S. trade or business
conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and (ii)&nbsp;if required by an applicable income tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, then the gain generally will be subject to U.S. federal income tax at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. If the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a corporation, under certain circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would
be subject also to a &#147;branch profits tax.&#148; The branch profits tax rate is 30%, although an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence
might provide for a lower rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U.S. Federal Estate Tax </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a
U.S. corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of
residence provides otherwise. The terms &#147;resident&#148; and &#147;nonresident&#148; are defined differently for U.S. federal estate tax purposes than for U.S. federal income tax purposes. Investors are urged to consult their own tax advisors
regarding the U.S. federal estate tax consequences of the ownership or disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Backup Withholding and
Information Reporting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Code and the Treasury regulations require those who make specified payments to report the payments to the
IRS. Among the specified payments are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is
reinforced by &#147;backup withholding&#148; rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer
identification number to the payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to
corporations, whether domestic or foreign, provided they establish such exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of dividends on common stock generally will not be subject to backup withholding, and payments of proceeds made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders by a broker upon a
sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder certifies its nonresident status (and we or our paying agent do not have
actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The certification procedures to claim treaty benefits described under
&#147;&#151;Dividends&#148; will generally satisfy the certification requirements necessary to avoid the backup withholding tax. We must report annually to the IRS any dividends paid to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among
other things, its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (and the broker does not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from
the disposition of shares of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker generally will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be subject to backup withholding and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment
is made outside of the United States, if you sell our common stock through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a U.S. person (including a foreign branch or office of such person); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;controlled foreign corporation&#148; for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign partnership if at any time during its tax year (a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
(b)&nbsp;the foreign partnership is engaged in a U.S. trade or business; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker has documentary evidence that the beneficial
owner is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding
rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign
financial institution (as specifically defined by the applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). This U.S. federal withholding tax of 30% will
also apply to dividends and the gross proceeds of a disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent with either a certification that it
does not have any substantial direct or indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The 30% federal withholding tax described in this paragraph cannot be reduced under an income tax treaty
with the United States or by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or similar documentation. The withholding tax described above will not apply if the foreign financial institution or
<FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from the rules. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits
of such taxes. Holders should consult with their own tax advisors regarding the possible implications of the withholding described herein. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the
United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above generally will apply to
proceeds from a sale or other disposition of common stock if such sale or other disposition occurs on or after January&nbsp;1, 2019 and currently apply to payments of dividends on our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES
OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_14"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions contained in an underwriting agreement
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we have agreed to sell to the underwriters named below, for whom Credit Suisse Securities (USA) LLC, Jefferies LLC and Stifel,
Nicolaus&nbsp;&amp; Company, Incorporated are acting as representatives, the following respective numbers of shares of common stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the underwriters are obligated to purchase all the shares of common
stock in the offering if any are purchased, other than those shares covered by the option to purchase additional shares described below. The underwriting agreement also provides that if an underwriter defaults the purchase commitments of <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the offering may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the
underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase on a pro rata basis up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares at the public offering price less the
underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of common stock initially at the public offering
price on the cover page of this prospectus and to selling group members at that price less a selling concession of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The underwriters and selling group members may allow a discount of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share on sales to other broker/dealers. After the public offering the underwriters may change the public offering price<B> </B>and concession and discount to broker/dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation we will pay: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and Commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our out of pocket expenses for this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for up to $35,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our executive officers and directors (other than Dr. Lydon) have agreed with the underwriters that, for a period of 90
days after the date of this prospectus, and Dr. Lydon and entities affiliated with Frazier Healthcare have agreed with the underwriters that, for a period of 60 days after the date of this prospectus, subject to certain exceptions, we and they will
not (1)&nbsp;offer, sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of (or enter into any
transaction which is designed to, or might reasonably be expected to, result in the disposition), directly or indirectly, including the filing (or participation in the filing) with the SEC of a registration statement under the Securities Act to
register, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock or warrants or other rights to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquire shares of our common stock of which such officer, director or holder is now, or may in the future become, the beneficial owner (within the meaning of Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), or (2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic benefits or risks of
ownership of such common stock, securities, warrants or other rights to acquire common stock, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of common stock or other securities, in cash or
otherwise, or (3)&nbsp;publicly disclose the intention to enter into any transaction described in clause (1)&nbsp;or (2)&nbsp;above, except with the prior written consent of Credit Suisse Securities (USA) LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions on our executive officers and directors and their affiliates above do not apply to the following, subject to certain
limitations set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities as a bona fide gift; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of securities to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or any member of the immediate family of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities to affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of our common stock or securities convertible or exchangeable into shares of our common stock acquired in open market purchases after the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entry into any trading plan established pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise of options, warrants or other rights to acquire shares of common stock in accordance with their terms pursuant to an employee benefit plan, option, warrant or other right; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares upon termination of service of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers by certain stockholders of shares purchased in this offering; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a liquidation, tender offer, merger, consolidation or similar transaction that results
in all of our stockholders having the right to exchange their securities for cash, securities or other property. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We<I>
</I>have agreed to indemnify the underwriters against liabilities under the Securities Act, or contribute to payments that the underwriters may be required to make in that respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Select Market under the symbol &#147;ANAB.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions and penalty bids and passive market making in accordance with Regulation M under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a
covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of additional shares that they have the option to purchase. In a naked short
position, the number of shares involved is greater than the number of additional shares that they have the option to purchase. The underwriters may close out any covered short position by either exercising their option to purchase additional shares
and/or purchasing shares in the open market. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to
close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares through their option. If the
underwriters sell more shares than could be covered by the option to purchase additional shares, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if
the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In passive market making, market makers in the common stock who are underwriters or prospective underwriters may, subject to limitations, make bids for or purchases of our common stock until the time, if any, at which a
stabilizing bid is made. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the
effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result the price of our common stock may be higher than the price that might otherwise exist in
the open market. These transactions may be effected on The NASDAQ Global Select Market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by one or more of the underwriters, or selling group
members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling
group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selling Restrictions: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is not intended to constitute an offer or solicitation to purchase or invest in the securities described herein. The securities
may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading facility in Switzerland. Neither this document nor
any other offering or marketing material relating to the securities constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the
listing rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland, and neither this document nor any other offering or marketing material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, nor the Company
nor the securities have been or will be filed with or approved by any Swiss regulatory authority. The securities are not subject to the supervision by any Swiss regulatory authority, e.g., the Swiss Financial Markets Supervisory Authority FINMA
(FINMA), and investors in the securities will not benefit from protection or supervision by such authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the
European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive
(each, a Relevant Member State), each underwriter represents and agrees that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, it has not made and will not make an offer of
securities which are the subject of the offering contemplated by this prospectus to the public in that Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the
Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to
any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the
securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression Prospectus Directive means Directive 2003/71/EC (and amendments thereto, including the 2010 PD
Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the underwriters severally represents warrants and agrees as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the
Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21 of the FSMA does not apply to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">it has complied with, and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Canadian Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of shares of common stock offered hereby in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British
Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares offered hereby in
Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable
Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By purchasing shares of common stock offered hereby in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to
us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as
defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>,
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of
Interest </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby notified that the underwriters are relying on the exemption set out in section 3A.3 or
3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I><I></I>&nbsp;from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the
offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible
for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to
satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers of shares of common stock offered hereby should consult their own legal and tax advisors with respect to the tax
consequences of an investment in the shares in their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering material relating to the securities described in this prospectus has been submitted to the
clearance procedures of the Autorit&eacute; des March&eacute;s Financiers or of the competent authority of another member state of the European Economic Area and notified to the Autorit&eacute; des March&eacute;s Financiers. The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the securities has been or will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">used in connection with any offer for subscription or sale of the securities to the public in France. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such offers, sales and distributions will be made in France only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to qualified investors (<I>investisseurs qualifi&eacute;s) </I>and/or to a restricted circle of investors (<I>cercle restreint d&#146;investisseurs</I>), in each case investing for their own account, all as defined in,
and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT
STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code mon&eacute;taire et financier; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in a transaction that, in accordance with article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French Code mon&eacute;taire et financier and article <FONT STYLE="white-space:nowrap">211-2</FONT>
of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the Autorit&eacute; des March&eacute;s Financiers, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French Code mon&eacute;taire et financier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Republic of Italy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of securities has not been registered with the <I>Commissione Nazionale per le Societ&agrave; e la Borsa </I>(&#147;CONSOB&#148;)
pursuant to Italian securities legislation and, accordingly, no securities may be offered, sold or delivered, nor copies of this prospectus supplement, the accompanying prospectus or any other documents relating to the securities may not be
distributed in Italy except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to &#147;qualified investors&#148;, as referred to in Article 100 of Legislative Decree No.&nbsp;58 of
24&nbsp;February 1998, as amended (the &#147;Decree No.&nbsp;58&#148;) and defined in Article 26, paragraph 1, letter d) of CONSOB Regulation No.&nbsp;16190 of 29&nbsp;October 2007, as amended (&#147;Regulation No.&nbsp;16190&#148;) pursuant to
Article <FONT STYLE="white-space:nowrap">34-ter,</FONT> paragraph 1, letter. b) of CONSOB Regulation No.&nbsp;11971 of 14&nbsp;May 1999, as amended (&#147;Regulation No.&nbsp;11971&#148;); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in any other circumstances where an express exemption from compliance with the offer restrictions applies, as provided under Decree
No.&nbsp;58 or Regulation No.&nbsp;11971. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer, sale or delivery of the securities or distribution of copies of this prospectus
supplement, the accompanying prospectus or any other documents relating to the securities in the Republic of Italy must be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) made by
investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with Legislative Decree No.&nbsp;385 of 1&nbsp;September 1993, as amended (the &#147;Banking Law&#148;), Decree
No.&nbsp;58 and Regulation No.&nbsp;16190 and any other applicable laws and regulations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in compliance with Article 129 of the
Banking Law, and the implementing guidelines of the Bank of Italy, as amended; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in compliance with any other applicable
notification requirement or limitation which may be imposed, from time to time, by CONSOB or the Bank of Italy or other competent authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that, in accordance with Article <FONT STYLE="white-space:nowrap">100-bis</FONT> of Decree No.&nbsp;58, where no exemption from
the rules on public offerings applies, the subsequent distribution of the securities on the secondary market in Italy must be made in compliance with the public offer and the prospectus requirement rules provided under Decree No.&nbsp;58 and
Regulation No.&nbsp;11971. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, securities which are initially offered and placed in Italy or abroad to
qualified investors only but in the following year are regularly (&#147;<I>sistematicamente</I>&#148;) distributed on the secondary market in Italy to <FONT STYLE="white-space:nowrap">non-qualified</FONT> investors become subject to the public offer
and the prospectus requirement rules provided under Decree No.&nbsp;58 and Regulation No.&nbsp;11971. Failure to comply with such rules may result in the sale of the securities being declared null and void and in the liability of the intermediary
transferring the securities for any damages suffered by such <FONT STYLE="white-space:nowrap">non-qualified</FONT> investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in Germany </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a Prospectus Directive-compliant prospectus in accordance with the German
Securities Prospectus Act (<I>Wertpapierprospektgesetz</I>) and does therefore not allow any public offering in the Federal Republic of Germany (&#147;Germany&#148;) or any other Relevant Member State pursuant to &#167; 17 and &#167; 18 of the
German Securities Prospectus Act. No action has been or will be taken in Germany that would permit a public offering of the securities, or distribution of a prospectus or any other offering material relating to the securities. In particular, no
securities prospectus (<I>Wertpapierprospekt</I>) within the meaning of the German Securities Prospectus Act or any other applicable laws of Germany, has been or will be published within Germany, nor has this prospectus been filed with or approved
by the German Federal Financial Supervisory Authority (<I>Bundesanstalt f&uuml;r Finanzdienstleistungsaufsicht</I>) for publication within Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each manager will represent, agree and undertake, (i)&nbsp;that it has not offered, sold or delivered and will not offer, sell or deliver the
securities within Germany other than in accordance with the German Securities Prospectus Act (<I>Wertpapierprospektgesetz</I>) and any other applicable laws in Germany governing the issue, sale and offering of securities, and (ii)&nbsp;that it will
distribute in Germany any offering material relating to the securities only under circumstances that will result in compliance with the applicable rules and regulations of Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is strictly for use of the person who has received it. It may not be forwarded to other persons or published in Germany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Arab Emirates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates
(&#147;U.A.E.&#148;) other than in compliance with the laws of the U.A.E. Prospective investors in the Dubai International Financial Centre should have regard to the specific notice to prospective investors in the Dubai International Financial
Centre set out above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus supplement and the accompanying prospectus does not constitute a
public offer of securities in the U.A.E. in accordance with the Commercial Companies Law (Federal Law No.&nbsp;8 of 1984 of the U.A.E., as amended) or otherwise and is not intended to be a public offer. This prospectus supplement and the
accompanying prospectus have not been approved by or filed with the Central Bank of the United Arab Emirates, the Emirates Securities and Commodities Authority or the Dubai Financial Services Authority, or DFSA. If you do not understand the contents
of this prospectus supplement or the accompanying prospectus, you should consult an authorized financial adviser. This prospectus supplement and the accompanying prospectus are provided for the benefit of the recipient only, and should not be
delivered to, or relied on by, any other person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document relates to an exempt offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority. This
document is intended for distribution only to persons of a type specified in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
those rules. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority has no responsibility for reviewing or verifying any documents in connection
with exempt offers. The Dubai Financial Services Authority has not approved this document nor taken steps to verify the information set out in it, and has no responsibility for it. The notes which are the subject of the offering contemplated by this
offering memorandum may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the notes offered should conduct their own due diligence on the notes. If you do not understand the contents of this document you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Kingdom of Saudi Arabia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations issued by the Capital Market Authority of Saudi Arabia (the &#147;Capital Market Authority&#148;). The Capital Market Authority does not make any representations as to the accuracy or completeness of this prospectus, and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If a prospective purchaser does not understand the contents of this prospectus he or she should consult an authorised financial adviser. By accepting this prospectus and other information relating to the
offering of the securities in the Kingdom of Saudi Arabia, each recipient represents that he is a &#147;sophisticated investor&#148;, as set out in the prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the
Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust
funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters purchasing for their own account, venture capital funds, entities with equity in excess of NIS
50&nbsp;million and qualified individuals, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors. Qualified investors may be required to submit written confirmation that they meet
the criteria for one of the categories of investors set forth in the prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in South Africa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, the securities are not offered, and the offer of our securities shall not be
transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the offer, transfer, sale, renunciation or delivery is to duly registered banks, mutual banks, financial services provider, financial institution, the Public Investment Corporation (in each case registered as such in
South Africa), a person who deals with securities in their ordinary course of business, or a wholly owned subsidiary of a bank, mutual bank, authorized services provider or financial institution, acting as agent in the capacity of an authorized
portfolio manager for a pension fund (duly registered in South Africa), or as manager for a collective investment scheme(registered in South Africa); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than R1,000,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not, nor is it intended to, constitute an &#147;offer to the public&#148; (as that term is defined in the South African
Companies Act, 2008 (the &#147;SA Companies Act&#148;) and does not, nor is it intended to, constitute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a prospectus prepared and registered under the SA Companies Act. This document is not an &#147;offer to the public&#148; and must not be acted on or relied on by persons who do not fall within
Section&nbsp;96(1)(a) of the SA Companies Act (such persons being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only
with relevant persons. A South African resident person or company or any <FONT STYLE="white-space:nowrap">non-South</FONT> African company which is a subsidiary of a South African company is not permitted to acquire the securities unless such person
has obtained exchange control approval to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;to &#147;professional investors&#148; as
defined in the Securities and Futures Ordinance (Cap.571) of Hong Kong and any rules made under that Ordinance, or (ii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies
Ordinance (Cap.32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the depositary securities may be issued or may be in the possession of any
person for the purpose of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to depositary securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under
that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and
any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation
for subscription or purchase, whether directly or indirectly, to persons in Singapore other than </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities
pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to
any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Residents of Malaysia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
securities may not be offered for subscription or purchase and no invitation to subscribe for or purchase such Certificates in Malaysia may be made, directly or indirectly, and this prospectus or any document or other materials in connection
therewith may not be distributed in Malaysia other than to persons falling within the categories specified under Schedule 6 or Section&nbsp;229(l)(b), Schedule 7 or Section&nbsp;230(l)(b) and Schedule 8 or Section&nbsp;257(3) of the Capital Market
and Services Act, 2007 of Malaysia. The Securities Commission of Malaysia shall not be liable for any <FONT STYLE="white-space:nowrap">non-disclosure</FONT> on the part of the Issuer and assumes no responsibility for the correctness of any
statements made or opinions or reports expressed in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of the securities offered by this prospectus, whether by sale or subscription, in the
People&#146;s Republic of China, or the PRC. The securities are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the securities without obtaining all prior
PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Korea </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the
decrees and regulations thereunder, or the FSCMA, and the securities have been and will be offered in Korea as a private placement under the FSCMA. None of the securities may be offered, sold or delivered directly or indirectly, or offered or sold
to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign
Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The securities have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the
purchaser of the securities shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the securities. By the purchase of the securities,
the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the securities pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Taiwan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities
laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or
approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus supplement does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations
Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the securities may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act. The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia
in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the
Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian
<FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. This prospectus supplement contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It
does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus supplement is appropriate to their needs, objectives and
circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Cayman Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute an invitation or offer to the public in the Cayman Islands of the securities, whether by way of sale or
subscription. The underwriters have not offered or sold, and will not offer or sell, directly or indirectly, any securities in the Cayman Islands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Bermuda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business
Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such
persons are permitted to do so under applicable Bermuda legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription
by us or on our behalf. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (each a BVI Company), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been, and will not be, registered with the Financial
Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the securities for the purposes of the Securities and Investment Business Act, 2010, or SIBA or the Public Issuers Code of the
British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be offered to persons located in the British Virgin Islands who are &#147;qualified
investors&#148; for the purposes of SIBA. Qualified investors include (i)&nbsp;certain entities which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and
public, professional and private mutual funds; (ii)&nbsp;a company, any securities of which are listed on a recognised exchange; and (iii)&nbsp;persons defined as &#147;professional investors&#148; under SIBA, which is any person (a)&nbsp;whose
ordinary business involves, whether for that person&#146;s own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of our property; or (b)&nbsp;who has signed a
declaration that he, whether individually or jointly with his spouse, has net worth in excess of US$1,000,000 and that he consents to being treated as a professional investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San
Francisco, California. Certain legal matters relating to the offering will be passed upon for the underwriters by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_16"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of AnaptysBio, Inc. as of December&nbsp;31, 2015 and 2016, and for each of the years in the three-year
period ended December&nbsp;31, 2016, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, an independent registered public accounting firm, appearing elsewhere herein, and upon the
authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_17"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect
to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further
information about us and the common stock offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is
filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. A copy of the registration statement
and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from
that office. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information about the public reference room. The SEC also
maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, file periodic reports and
other information with the SEC. These periodic reports and other information are available for inspection and copying at the SEC&#146;s public reference facilities and the website of the SEC referred to above. We also maintain a website at
www.anaptysbio.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the
inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_18"></A>INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we
file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes
information incorporated by reference that we filed with the SEC prior to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus and the registration statement of which this
prospectus is a part the information or documents listed below that we have filed with the SEC (Commission <FONT STYLE="white-space:nowrap">File&nbsp;No.&nbsp;001-37985).</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;8, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;for</FONT> the quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017, filed with the SEC on May&nbsp;12, 2017 and August&nbsp;10,
2017, respectively; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;2, 2017, July&nbsp;27, 2017 and August&nbsp;24, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including
exhibits to these documents. You should direct any requests for documents to 10421 Pacific Center Court, Suite 200 San Diego, CA 92121, telephone (858) <FONT STYLE="white-space:nowrap">362-6295.&nbsp;Copies</FONT> of the above reports may also be
accessed from our website at www.anaptysbio.com. We do not incorporate the information from our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our
website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified,
superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </P> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g71b77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Credit Suisse </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </P>
<P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in
connection with the sale of the common stock being registered. All amounts shown are estimates except for the SEC registration fee and the FINRA filing fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount<BR>Paid or<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;14. INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#146;s board of directors to grant,
indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&nbsp;145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances
for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General
Corporation Law, the Registrant&#146;s restated certificate of incorporation to be effective in connection with the closing of this offering contains provisions that eliminate the personal liability of its directors for monetary damages for any
breach of fiduciary duties as a director, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to the Registrant or its stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">under Section&nbsp;174 of the Delaware General Corporation Law (regarding unlawful dividends and stock purchases); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by
the Delaware General Corporation Law, the Registrant&#146;s restated bylaws to be effective upon the closing of this offering, provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject
to limited exceptions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rights conferred in the restated bylaws are not exclusive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered
into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the
Registrant&#146;s restated certificate of incorporation and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which
indemnification is sought. Reference is also made to Section&nbsp;9 of the underwriting agreement to be filed as Exhibit 1.1 to this registration statement, which provides for the indemnification of executive officers, directors and controlling
persons of the Registrant against certain liabilities. The indemnification provisions in the Registrant&#146;s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the
Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant&#146;s directors and executive officers for liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant currently carries liability insurance for its directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the following documents filed as exhibits to this Registration Statement regarding relevant indemnification provisions
described above and elsewhere herein: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:62.40pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Underwriting Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restated Certificate of Incorporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restated Bylaws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Amended and Restated Investors&#146; Rights Agreement dated July&nbsp;13, 2015 among the
Registrant and certain of its stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Indemnity Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;15. RECENT SALES OF UNREGISTERED SECURITIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following lists set forth information regarding all securities sold or granted by us within the past three years that were not registered
under the Securities Act, and the consideration, if any, received by us for such securities: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Stock Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between August&nbsp;31, 2014 until January&nbsp;26, 2017, the Registrant granted options to purchase 1,760,974 shares of common stock under its
2006 Equity Incentive Plan to its directors, officers, employees, consultants, and other service providers with per share exercise prices ranging from $0.70 to $11.34. During this same period, the Registrant issued 174,139 shares of common stock
upon exercise of stock options previously issued under the 2006 Equity Incentive Plan to its directors, officers, employees, consultants, and other service providers for cash consideration in the aggregate amount of $195,180. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock options and the common stock issuable upon the exercise of such options as described in this section (a)&nbsp;of Item 15 were issued
pursuant to written compensatory plans or arrangements with the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">employees and directors in reliance on the exemption provided by Rule 701 promulgated under the Securities Act. All recipients either received adequate
information about the Company or had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Warrants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, the Registrant issued warrants to accredited investors to purchase an aggregate of 41,208 shares of the
Registrant&#146;s Series C convertible preferred stock. The preferred stock warrants have a per share exercise price of $4.55. The securities issued in this transaction were exempt from the registration requirements of the Securities Act in reliance
upon Section&nbsp;4(a)(2) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the Registrant issued warrants to accredited investors to purchase
an aggregate of 82,416 shares of the Registrant&#146;s Series C convertible preferred stock. The preferred stock warrants have a per share exercise price of $4.55. The securities issued in this transaction were exempt from the registration
requirements of the Securities Act in reliance upon Section&nbsp;4(a)(2) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;31, 2017, the
Registrant has issued a total of 397,445 shares of common stock pursuant to the exercise of warrants, each with an exercise price of $4.55 per share. The securities issued in this transaction were exempt from the registration requirements of the
Securities Act in reliance upon Section 4(a)(2) under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>(c) Sales of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, the Registrant issued an aggregate of 5,490,973 shares of the Registrant&#146;s Series D convertible preferred stock at a
purchase price of $7.42 per share for an aggregate purchase price of $40.8&nbsp;million to 19 purchasers that represented to us that they are each a sophisticated accredited investor and qualified institutional buyer. The securities issued in this
transaction were exempt from registration requirements of the Securities Act in reliance on Rule 506 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering, and the Registrant
believes each transaction was exempt from the registration requirements of the Securities Act as stated above. All recipients of the foregoing transactions either received adequate information about the Registrant or had access, through their
relationships with the Registrant, to such information. Furthermore, the Registrant affixed appropriate legends to the share certificates and instruments issued in each foregoing transaction setting forth that the securities had not been registered
and the applicable restrictions on transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>by&nbsp;Reference</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:42.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Furnished</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement, including Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000137005317000005/anab-033117x10qxexx31.htm">Restated Certificate of Incorporation. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">10-Q</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">001-37985</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;12, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex34.htm">Restated Bylaws. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9,&nbsp;2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>by&nbsp;Reference</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:42.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Furnished</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515412604/d942137dex41.htm">Form of Common Stock Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;23,&nbsp;2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex42.htm">Fourth&nbsp;Amended&nbsp;and&nbsp;Restated Investors&#146; Rights Agreement, dated July&nbsp;
13, 2015, by and among the Registrant and certain of its stockholders. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Fenwick&nbsp;&amp; West LLP.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex101.htm">Form&nbsp;of&nbsp;Indemnity&nbsp;Agreement.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312517010405/d320192dex102.htm">Amended and Restated 2006 Equity&nbsp;Incentive&nbsp;Plan&nbsp;and&nbsp;forms of award agreements. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;17, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312517010405/d320192dex103.htm">2017&nbsp;Equity&nbsp;Incentive&nbsp;Plan&nbsp;and forms of award agreements. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;17, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312517010405/d320192dex104.htm">2017&nbsp;Employee&nbsp;Stock&nbsp;Purchase Plan and forms of award agreements. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;17, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex105.htm">Employment Agreement, effective&nbsp;as&nbsp;of&nbsp;January&nbsp;1,&nbsp;2012, by and between the Registrant and&nbsp;Hamza&nbsp;
Suria,&nbsp;as&nbsp;amended.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312516805335/d320192dex106.htm">Employment Agreement, effective&nbsp;as&nbsp;of&nbsp;March&nbsp;22,&nbsp;2016, by and between the Registrant and Matthew Moyle. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.7&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex108.htm">Employment Agreement, effective as of October&nbsp;20, 2014, by and between the Registrant and Marco Londei.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.8&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="d453477dex108.htm">Employment Agreement, effective&nbsp;as&nbsp;of&nbsp;January&nbsp;9,&nbsp;2017, by and between the Registrant and Dominic Piscitelli. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">X</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.9&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515412604/d942137dex108.htm">Office Lease, dated April&nbsp;19, 2011, by and between the Registrant and Kilroy Realty, L.P., as amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;23, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.10&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312516805335/d320192dex109.htm">Antibody Generation Agreement,&nbsp;dated&nbsp;December&nbsp;
22, 2011, by and between the Registrant and Celgene Corporation, as modified. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>by&nbsp;Reference</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:42.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Furnished</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.11&#043;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312516585556/d942137dex1010.htm">Collaboration and Exclusive License Agreement, dated March&nbsp;10,&nbsp;2014,&nbsp;by&nbsp;and&nbsp;
among the Registrant, TESARO, Inc. and TESARO Development, Ltd., as amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.12&#043;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex1012.htm">License Agreement, dated August&nbsp;30, 2006, by and between the Registrant and Medical Research Council, as amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.13&#043;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312515315918/d942137dex1013.htm"><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Research and Commercial License Agreement, dated May&nbsp;
15, 2009, by and between the Registrant and Millipore Corporation. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.14&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000119312516465517/d942137dex1013.htm">Loan&nbsp;and&nbsp;Security&nbsp;Agreement, dated December&nbsp;
24, 2014, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank, as amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">S-1/A</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">333-206849</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;16, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21.1&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="http://www.sec.gov/Archives/edgar/data/1370053/000156459017003710/anab-ex211_109.htm">Subsidiaries of the Registrant.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">10-K</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">001-37985</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;8, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consent of KPMG LLP, an independent registered public accounting firm.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consent of Fenwick&nbsp;&amp; West LLP (included in Exhibit 5.1).</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc453477_19">Power&nbsp;of&nbsp;Attorney&nbsp;(reference&nbsp;is made to the signature page hereto). </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#043;</B></TD>
<TD ALIGN="left" VALIGN="top">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;17. UNDERTAKINGS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_19"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this amendment to the registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the&nbsp;&nbsp;&nbsp;&nbsp;day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ANAPTYSBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hamza Suria</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes
and appoints Hamza Suria and Dominic G. Piscitelli, and each of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, each with full power of
substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule
462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as
fully for all intents and purposes as he or her might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, or
their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the
Securities Act of 1933, this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> has been signed by the following persons in the capacities and on the dates indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hamza&nbsp;Suria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and Director</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dominic&nbsp;G.&nbsp;Piscitelli</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal&nbsp;Accounting&nbsp;and&nbsp;Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carol&nbsp;G.&nbsp;Gallagher,&nbsp;Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nicholas&nbsp;B.&nbsp;Lydon,&nbsp;Ph.D.,&nbsp;FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hollings Renton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John Schmid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James A. Schoeneck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James N. Topper, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J. Anthony Ware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2017</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
<B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B><I>Agreement</I></B>&#148;) is made effective from January 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2017 (the &#147;Effective Date&#148;) by and
among <B>A<SMALL>NAPTYSBIO</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>. (the &#147;<B><I>Company</I></B>&#148;) and Dominic Piscitelli (&#147;<B><I>CFO</I></B>&#148;). The Company and CFO are hereinafter collectively referred to as the
&#147;<B><I>Parties</I></B>&#148;, and individually referred to as a &#147;<B><I>Party</I></B>&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITAL</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company desires to employ CFO, and CFO is willing to accept such employment by Company, on the terms and subject to the conditions set
forth in this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable
consideration, the Parties, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. E<SMALL>MPLOYMENT</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.1 Title</B>. Effective as of the Effective Date, CFO&#146;s position shall be Chief Financial Officer of the Company, subject to the terms
and conditions set forth in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.2 Term</B>. The term of this Agreement shall begin on the Effective Date and shall
continue until it is terminated pursuant to Section&nbsp;4 herein (the &#147;<B><I>Term</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.3 Duties</B>. CFO shall do
and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the position of Chief Financial Officer. CFO shall report to the Chief Executive Officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.4 Policies and Practices</B>. The employment relationship between the Parties shall be governed by this Agreement and by the policies and
practices established by the Company and/or the Board, or any designated committee thereof. In the event that the terms of this Agreement differ from or are in conflict with the Company&#146;s policies or practices or the Company&#146;s Employee
Handbook, this Agreement shall control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>1.5 Location</B>. Unless the Parties otherwise agree in writing, during the Term CFO shall
perform the services CFO is required to perform pursuant to this Agreement at the Company&#146;s offices in San Diego, California, provided, however, that the Company may from time to time require CFO to travel temporarily to other locations in
connection with the Company&#146;s business. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. L<SMALL>OYALTY</SMALL>; N<SMALL>ONCOMPETITION</SMALL>; N<SMALL>ONSOLICITATION</SMALL>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1 Loyalty</B>. During CFO&#146;s employment with the Company, CFO shall devote CFO&#146;s full business energies, interest,
abilities and productive time to the proper and efficient performance of CFO&#146;s duties under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2 Agreement not to
Participate in Company&#146;s Competitors</B>. During CFO&#146;s employment with the Company, CFO agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by CFO to be adverse or
antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below).
Ownership by CFO, in professionally managed funds over which CFO does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation
with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market shall not constitute a breach of this Section. For purposes of this Agreement, &#147;Affiliate,&#148; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is
controlled by or is under common control with such specified entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.3 Covenant not to Compete</B>. During CFO&#146;s employment with
the Company, CFO shall not engage in competition with the Company and/or any of its Affiliates in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, owner,
<FONT STYLE="white-space:nowrap">co-owner,</FONT> consultant, in any phase of the business of developing, manufacturing and marketing of products or services that directly compete with the products or services of the Company, except with the prior
written consent of the CEO. CFO shall be entitled to request written consent of the CEO with respect to potential advisory and/or director opportunities presented to CFO by a third party, which CFO believes in good faith will not interfere or
compete with the <FONT STYLE="white-space:nowrap">on-going</FONT> business of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. C<SMALL>OMPENSATION</SMALL>
<SMALL>OF</SMALL> CFO. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.1 Base Salary</B>. The Company shall pay CFO a base salary at the annualized rate of $365,000 (the
&#147;<B><I>Base Salary</I></B>&#148;), less payroll deductions and all required withholdings, payable in regular periodic installments in accordance with the Company&#146;s normal payroll practices. The Base Salary shall be prorated for any partial
year of employment on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> fiscal year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.2 Discretionary Bonus</B>. At the
sole discretion of the Board and Chief Executive Officer, promptly following each calendar year of employment CFO shall be eligible to receive a discretionary cash bonus of up to 30% of CFO&#146;s then-current base salary (the
&#147;<B><I>Bonus</I></B>&#148;), based on CFO&#146;s achievement relative to certain performance goals (&#147;<B><I>Performance Goals</I></B>&#148;) to be established by the Chief Executive Officer in writing in a manner reasonably consistent with
the Company&#146;s priorities. The determination of whether CFO has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Board and Chief Executive
Officer in their sole and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
absolute discretion. In order to be eligible to earn or receive any Bonus, CFO must remain employed by the Company through and including the date of payment of such Bonus. For the first calendar
year of CFO&#146;s employment with Company, the Bonus payable shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> in accordance with the percentage of the calendar year that the CFO is an employee of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.3 <FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</B>. Conditional upon the CFO initiating employment with the Company as of the
Effective Date, Company agrees to pay CFO an aggregate <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $100,000, of which <FONT STYLE="white-space:nowrap">one-half</FONT> ($50,000) is payable to CFO within thirty (30)&nbsp;days of the
Effective Date, and the second half ($50,000) will be payable thirty (30)&nbsp;days subsequent to the earlier of (i)&nbsp;closing of an initial public offering of the Company&#146;s stock and (ii)&nbsp;the six (6)&nbsp;month anniversary of the
Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.4 Relocation</B>. CFO in good faith intends to relocate his household to the San Diego area as soon as practical, but
no later than four (4)&nbsp;months following the Effective Date. Until such time as CFO relocates, CFO agrees to spend at least 4 days per week at the Company&#146;s offices in San Diego, unless as otherwise approved on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">week-to-week</FONT></FONT> basis by the Chief Executive Officer. The Company will cover the actual and reasonable costs, including <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> relocation, commuting and related tax expense, associated with CFO&#146;s relocation to the San Diego area, up to a maximum of $40,000, exclusive of any tax
<FONT STYLE="white-space:nowrap">gross-up</FONT> payment. CFO must remain employed by the Company through and including the date of payment of any such amounts payable under this Section&nbsp;3.4, and all such payments will be subject to any
necessary payroll deductions and all required withholdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.5 Stock Option</B>. As soon as practicable following the Effective Date,
CFO will be granted an option to purchase up to 1,191,695 shares of the Company&#146;s Common Stock (the &#147;<B><I>Base Option</I></B>&#148;) pursuant to the terms of the Company&#146;s 2006 Equity Incentive Plan, as amended from time to time (the
&#147;<B><I>Plan</I></B>&#148;). The Base Option shall be subject to vesting such that, subject to CFO&#146;s continued employment with the Company, 1/4 of the shares subject to the Base Option shall vest as of the first anniversary of the Effective
Date and l/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares subject to the Base Option shall vest in equal monthly installments on the monthly anniversary of the Effective Date of each month for the 36 months thereafter. The
exercise price per share of the Base Option will be equal to the fair market value of a single share of Common Stock on the date the Base Option is granted, as determined in good faith by the Board. The Base Option will be governed by the Plan and
shall be granted pursuant to a separate stock option grant notice and stock option agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.6 Expense Reimbursements</B>. The
Company will reimburse CFO for all reasonable business expenses CFO incurs in conducting his duties hereunder, pursuant to the Company&#146;s usual expense reimbursement policies; provided that CFO supplies the appropriate substantiation for such
expenses no later than the end of the calendar month following the month in which such expenses were incurred by CFO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.7 Changes to
Compensation</B>. CFO&#146;s compensation will be reviewed annually and may be changed from time to time in the Company&#146;s sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.8 Employment Taxes</B>. All of CFO&#146;s compensation shall be subject to customary
withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.9 Benefits</B>.
CFO shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the
Company&#146;s senior management employees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.10 Holidays and Vacation</B>. CFO shall be eligible for paid holiday and vacation time in
accordance with Company policy as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. T<SMALL>ERMINATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.1 Termination by the Company</B>. CFO&#146;s employment with the Company is at will and may be terminated by the Company at any time and
for any reason, or for no reason, including, but not limited to, under the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.1 Termination by the Company for
Cause</B>. The Company may terminate CFO&#146;s employment under this Agreement for &#147;Cause&#148; (as defined below) by delivery of written notice to CFO. Any notice of termination given pursuant to this section shall effect termination as of
the date of the notice, or as of such other date specified in the notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.2 Termination by the Company without Cause</B>. The
Company may terminate CFO&#146;s employment under this Agreement without Cause at any time and for any reason, or for no reason. Such termination shall be effective on the date CFO is so informed, or as otherwise specified by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.2 Termination by CFO</B>. CFO may terminate his employment with the Company at any time and for any reason, or for no reason, upon thirty
(30)&nbsp;days written notice to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.3 Termination for Death or Disability</B>. CFO&#146;s employment with the Company shall
automatically terminate effective upon the date of CFO&#146;s death or Disability (as defined in the Plan). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.4 Termination by Mutual
Agreement of the Parties</B>. CFO&#146;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.5 Compensation upon Termination</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.5.1 Death or Disability</B>. If CFO&#146;s employment is terminated by death or Disability, the Company shall pay to CFO, or to
CFO&#146;s heirs, CFO&#146;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall thereafter have no further obligations to CFO and/or CFO&#146;s heirs under this Agreement, except as otherwise provided by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.5.2 Termination For Cause</B>. If the Company terminates CFO&#146;s employment for Cause, then the Company shall pay CFO&#146;s accrued
and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings. The Company shall thereafter have no further
obligations to CFO under this Agreement, except as otherwise provided by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.5.3 Termination by Company Without Cause or by CFO for
Good Reason Not In Connection with a Change in Control</B>. If the Company terminates CFO&#146;s employment without Cause or if CFO resigns his employment for Good Reason, in either case at any time other than upon the occurrence of, or within the
13 months immediately following, the effective date of a &#147;<B><I>Change in Control</I></B>&#148; (as defined in the Plan), the Company shall pay CFO&#146;s accrued and unpaid base salary and accrued and unused vacation benefits earned through
the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings. In addition to the above, if CFO furnishes to the Company an executed waiver and release of claims in the form attached hereto as
<B>Exhibit A</B> (or in such other form as may be specified by the Company) (the &#147;<B><I>Release</I></B>&#148;) within the time period specified therein, but in no event later than 45 days following CFO&#146;s termination, and if CFO allows such
Release to become effective in accordance with its terms, then (i)&nbsp;CFO shall be entitled to severance in the form of continuation of his base salary, at the base salary rate equal to the greater of the rate in effect at the time of termination
or immediately prior to the event giving rise to the Good Reason (the &#147;<B><I>Severance Payments</I></B>&#148;), for a period of nine (9)&nbsp;months following the termination date (the &#147;<B><I>Severance Period</I></B>&#148;), and
(ii)&nbsp;the Company will pay directly to the insurance provider the premium for COBRA continuation coverage for CFO and CFO&#146;s family during the Severance Period or until he obtains new employment, whichever comes first (the &#147;<B><I>COBRA
Coverage</I></B>&#148;); provided, however, that notwithstanding anything herein, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA Coverage benefit without potentially violating, or being subject to an
excise tax under, applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act), the Company will in lieu thereof provide to CFO a taxable monthly payment, payable on the last day of a given month, in an amount
equal to the monthly COBRA Coverage that CFO would be required to pay to continue CFO&#146;s group health coverage in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA coverage). The
Severance Payments will be subject to standard payroll deductions and withholdings and will be made on the Company&#146;s regular payroll cycle, provided, however, that any Severance Payments otherwise scheduled to be made prior to the effective
date of the Release shall accrue and be paid in the first payroll period that follows such effective date. The Company shall thereafter have no further obligations to CFO under this Agreement, except as otherwise provided by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.5.4 Termination by Company Without Cause or by CFO for Good Reason In Connection with a Change in Control</B>. If the Company terminates
CFO&#146;s employment without Cause or if CFO resigns his employment for Good Reason, in either case upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay CFO&#146;s
accrued and unpaid base salary and accrued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings. In addition, if CFO furnishes to
the Company an executed Release within the time period specified therein, but in no event later than 45 days following CFO&#146;s termination, and if CFO allows such Release to become effective in accordance with its terms, then CFO shall be
entitled to: (1)&nbsp;the Severance Payments and COBRA coverage described in Section&nbsp;4.5.3 above and (2)&nbsp;accelerated vesting of any unvested shares subject to the Base Option, such that CFO shall become vested in 100% of the shares subject
to such Base Option on the effective date of the Release. The Company shall thereafter have no further obligations to CFO under this Agreement, except as otherwise provided by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.6 Definitions</B>. For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.6.1 &#147;</B><B><I>Cause</I></B><B>&#148;</B> shall mean the occurrence of any one or more of the following: (i)&nbsp;CFO&#146;s
commission of any crime involving fraud, dishonesty or moral turpitude; (ii)&nbsp;CFO&#146;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material
harm to the business of the Company; (iii)&nbsp;CFO&#146;s intentional, material violation of any contract or agreement between CFO and the Company or any statutory duty CFO owes to the Company; or (iv)&nbsp;CFO&#146;s conduct that constitutes gross
insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company; <I>provided</I>, <I>however</I>, that the action or conduct described in clauses
(iii)&nbsp;and (iv) above will constitute &#147;Cause&#148; only if such action or conduct continues after the Company has provided CFO with written notice thereof and thirty (30)&nbsp;days to cure, or otherwise remedy to the extent possible under
direct control of the CFO, the same. An occurrence of &#147;Cause&#148; as set forth in the preceding sentence shall be based upon a good faith determination by the Board. CFO&#146;s Disability shall not constitute Cause as set forth herein. The
determination that a termination is for Cause shall be by the Board in its sole and exclusive judgment and discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.6.2
&#147;</B><B><I>Good Reason</I></B><B>&#148;</B> shall mean any of the following actions: (i)&nbsp;the assignment to CFO of any duties or responsibilities that results in a material diminution in CFO&#146;s function (for Section&nbsp;4.5.4, as in
effect immediately prior to the effective date of the Change in Control); <I>provided</I>, <I>however</I>, that a change in CFO&#146;s title or reporting relationships shall not provide the basis for a voluntary termination with Good Reason;
(ii)&nbsp;a reduction by the Company in CFO&#146;s annual base salary as in effect immediately prior to the effective date of the Change in Control; <I>provided</I>, <I>however</I>, that Good Reason shall not be deemed to have occurred in the event
of a reduction in CFO&#146;s annual base salary that is pursuant to a salary reduction program affecting substantially all of the employees of the Company and that does not adversely affect CFO to a greater extent than other similarly situated
employees; or (iii)&nbsp;a relocation of CFO&#146;s primary business office to a location more than 50 miles from the location of CFO&#146;s primary business office and which increases the CFO&#146;s commute (for Section&nbsp;4.5.4, as in effect
immediately prior to the effective date of the Change in Control), except for required travel by CFO on the Company&#146;s business to an extent substantially consistent with CFO&#146;s business travel obligations prior to the effective date of the
Change in Control; <I>provided</I>, <I>that</I> CFO may not resign for Good Reason without first providing the Company with written notice within ninety (90)&nbsp;days of the date of the initial existence of the condition that CFO believes
constitutes Good Reason specifically identifying the acts or omissions constituting the grounds for Good Reason </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and a reasonable cure period of not less than thirty (30)&nbsp;days and not more than ninety (90)&nbsp;days following the date of such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.7 Survival of Certain Sections</B>. Sections 3.4, 3.6 and 4 through 18 of this Agreement will survive the termination of this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.8 Parachute Payment</B>. If any payment or benefit CFO would receive pursuant to this Agreement (&#147;<B><I>Payment</I></B>&#148;)
would (i)&nbsp;constitute a &#147;<B><I>Parachute Payment</I></B>&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;), and (ii)&nbsp;but for this sentence, be subject to
the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; shall be either (x)&nbsp;the largest portion of
the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in CFO&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest economic benefit
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the
manner that results in the greatest economic benefit for CFO. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount (as determined pursuant to
clause (x)&nbsp;in the preceding paragraph) is subject to the Excise Tax, CFO agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of
doubt, if the Reduced Amount is determined in accordance with clause (y)&nbsp;in the preceding paragraph, CFO will have no obligation to return any portion of the Payment pursuant to the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless CFO and the Company agree on an alternative accounting or law firm, the accounting firm then engaged by the Company for general tax
compliance purposes shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a
nationally recognized accounting, law or consulting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting, law or consulting firm required to be made hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall use commercially reasonable efforts such that the accounting, law or consulting firm engaged to make the determinations
hereunder shall provide its calculations, together with detailed supporting documentation, to CFO and the Company within 15 calendar days after the date on which CFO&#146;s right to a Payment is triggered (if requested at that time by CFO or the
Company) or such other time as requested by CFO or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.9 Application of Internal Revenue Code
Section</B><B></B><B>&nbsp;409A</B>. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the &#147;<B><I>Severance Benefits</I></B>&#148;) that constitute &#147;deferred
compensation&#148; within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meaning of Section&nbsp;409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively
&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;) shall not commence in connection with CFO&#146;s termination of employment unless and until CFO has also incurred a &#147;separation from service&#148; (as such term is defined
in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (&#147;<B><I>Separation From Service</I></B>&#148;), unless the Company reasonably determines that such amounts may be provided to CFO without causing CFO to
incur the additional 20% tax under Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that each installment of the Severance Benefits payments provided
for in this Agreement is a separate &#147;payment&#148; for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(i).</FONT> For the avoidance of doubt, it is intended that payments of the Severance Benefits
set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&nbsp;409A provided under Treasury Regulation Sections <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9).</FONT> However, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute &#147;deferred
compensation&#148; under Section&nbsp;409A and CFO is, on the termination of service, a &#147;specified employee&#148; of the Company or any successor entity thereto, as such term is defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, then, solely
to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section&nbsp;409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of: (i)&nbsp;the date that is six months and
one day after CFO&#146;s Separation From Service, or (ii)&nbsp;the date of CFO&#146;s death (such applicable date, the &#147;<B><I>Specified Employee Initial Payment Date</I></B>&#148;), the Company (or the successor entity thereto, as applicable)
shall (A)&nbsp;pay to CFO a lump sum amount equal to the sum of the Severance Benefit payments that CFO would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits
had not been so delayed pursuant to this Section and (B)&nbsp;commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary set forth herein, CFO shall receive the Severance Benefits described above, if and only if CFO duly
executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Release and permits the Release to become effective in accordance with its
terms. Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior to the effective date of the Release. Except to the extent that payments may be delayed until the
Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay CFO the Severance Benefits CFO would otherwise have received under
the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled. All amounts payable under the Agreement will be subject
to standard payroll taxes and deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>AND</SMALL> P<SMALL>ROPRIETARY</SMALL>
I<SMALL>NFORMATION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CFO has already executed, as a condition of CFO&#146;s employment with the Company, the Company&#146;s
standard form of Proprietary Information and Inventions Agreement (the &#147;<B><I>PIIA</I></B>&#148;). The PIIA remains in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. A<SMALL>SSIGNMENT</SMALL> <SMALL>AND</SMALL> B<SMALL>INDING</SMALL> E<SMALL>FFECT</SMALL>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Agreement shall be binding upon and inure to the benefit of CFO and CFO&#146;s heirs, executors, personal representatives,
assigns, administrators and legal representatives. Because of the unique and personal nature of CFO&#146;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by CFO. This
Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all
purposes. For this purpose, &#147;successor&#148; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or
business of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. N<SMALL>OTICES</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All notices or demands of any kind required or permitted to be given by the Company or CFO under this Agreement shall be given in writing and
shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>If to the Company</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10421
Pacific Center Court, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>If to CFO</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dominic
Piscitelli </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the
United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its
conflict of laws principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. I<SMALL>NTEGRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Agreement, including <B>Exhibit A</B> and the PIIA, contains the complete, final and exclusive agreement of the Parties relating to the
terms and conditions of CFO&#146;s employment and the termination of CFO&#146;s employment, and supersedes any and all prior and/or contemporaneous oral and written employment agreements or arrangements between the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. A<SMALL>MENDMENT</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Agreement cannot be amended or modified except by a written agreement signed by CFO and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. W<SMALL>AIVER</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party
against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. S<SMALL>EVERABILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not
render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most
accurately represents the Parties&#146; intention with respect to the invalid or unenforceable term, or provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.
I<SMALL>NTERPRETATION</SMALL>; C<SMALL>ONSTRUCTION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The headings set forth in this Agreement are for convenience of reference
only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but CFO has been encouraged to consult with, and has consulted with, CFO&#146;s own independent counsel and tax
advisors with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any
ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.
R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CFO represents and warrants that CFO is not restricted or
prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that CFO&#146;s execution and performance of this Agreement will not violate or breach any other agreements
between CFO and any other person or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15. C<SMALL>OUNTERPARTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and
the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16. A<SMALL>RBITRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To ensure the rapid and economical resolution of disputes that may arise in connection with CFO&#146;s employment with the Company, CFO and the
Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to CFO&#146;s employment, or the termination of that employment, will be resolved, to the fullest extent permitted by law, by final,
binding and confidential arbitration pursuant to both the substantive and procedural provisions of the Federal Arbitration Act in San Diego, California conducted by the Judicial Arbitration and Mediation Services/Endispute, Inc.
(&#147;<B><I>JAMS</I></B>&#148;), or its successors, under the then current rules of JAMS for employment disputes; provided that the arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to
award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written arbitration decision including the arbitrator&#146;s essential findings and conclusions and a statement of the award. Accordingly, CFO and the Company hereby
waive any right to a jury trial. Both CFO and the Company shall be entitled to all rights and remedies that either CFO or the Company would be entitled to pursue in a court of law. The Company shall pay any JAMS filing fee and shall pay the
arbitrator&#146;s fee. Nothing in this Agreement is intended to prevent either CFO or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing,
CFO and the Company each have the right to resolve any issue or dispute involving confidential, proprietary or trade secret information, or intellectual property rights, by Court action instead of arbitration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17. T<SMALL>RADE</SMALL> S<SMALL>ECRETS</SMALL> <SMALL>OF</SMALL> O<SMALL>THERS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is the understanding of both the Company and CFO that CFO shall not divulge to the Company and/or its subsidiaries any confidential
information or trade secrets belonging to others, including CFO&#146;s former employers, nor shall the Company and/or its Affiliates seek to elicit from CFO any such information. Consistent with the foregoing, CFO shall not provide to the Company
and/or its Affiliates, and the Company and/or its Affiliates shall not request, any documents or copies of documents containing such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18. A<SMALL>DVERTISING</SMALL> W<SMALL>AIVER</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CFO agrees to permit the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or
sales promotional literature concerning the products and/or services of the Company, or the machinery and equipment used in the provision thereof, in which CFO&#146;s name and/or pictures of CFO taken in the course of CFO&#146;s provision of
services to the Company appear. CFO hereby waives and releases any claim or right CFO may otherwise have arising out of such use, publication or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[R<SMALL>EMAINDER</SMALL> <SMALL>OF</SMALL> <SMALL>THIS</SMALL> <SMALL>PAGE</SMALL> <SMALL>INTENTIONALLY</SMALL> <SMALL>LEFT</SMALL>
<SMALL>BLANK</SMALL>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have executed this Agreement as of the dates below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hamza Suria</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; CFO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;8, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CFO:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic Piscitelli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>D<SMALL>OMINIC</SMALL> P<SMALL>ISCITELLI</SMALL></B><SMALL></SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dated: 1/8/17 </TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELEASE AND WAIVER OF CLAIMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE SIGNED ON OR FOLLOWING THE SEPARATION DATE ONLY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the payments and other benefits set forth in the Employment Agreement effective
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 201&nbsp;&nbsp;&nbsp;&nbsp;, to which this form is attached, I, Dominic Piscitelli, hereby furnish
<B>A<SMALL>NAPTYSBIO</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>. (the &#147;<B><I>Company</I></B>&#148;), with the following release and waiver (&#147;<B><I>Release and Waiver</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally
and completely release the Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the
&#147;<B><I>Released Parties</I></B>&#148;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date that I
sign this Agreement (collectively, the &#147;<B><I>Released Claims</I></B>&#148;). The Released Claims include, but are not limited to: (a)&nbsp;all claims arising out of or in any way related to my employment with the Company, or the termination of
that employment; (b)&nbsp;all claims related to my compensation or benefits from the Company including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership
interests in the Company; (c)&nbsp;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d)&nbsp;all tort claims, including claims for fraud, defamation, emotional distress, and
discharge in violation of public policy; and (e)&nbsp;all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, misclassification, attorneys&#146; fees, or other claims arising under the federal
Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#147;<B><I>ADEA</I></B>&#148;), the California Labor Code, and the California
Fair Employment and Housing Act (as amended). Notwithstanding the foregoing, the following are not included in the Released Claims (the &#147;<B><I>Excluded Claims</I></B>&#148;): (a) any rights or claims for indemnification I may have pursuant to
the charter or bylaws of the Company or under applicable law; (b)&nbsp;any rights or claims to unemployment compensation, funds accrued in my 401k account, or any vested equity incentives; (c)&nbsp;any rights that are not waivable as a matter of
law; or (d)&nbsp;any claims arising from the breach of this Agreement. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included
in the Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I also acknowledge that I have read and understand Section&nbsp;1542 of the California Civil Code which reads as
follows: &#147;<B>A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her
settlement with the debtor</B>.&#148; I hereby expressly waive and relinquish all rights and benefits under that Section and any law of any jurisdiction, including New York, of similar effect with respect to any claims I may have against the
Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I acknowledge that, among other rights, I am waiving and releasing any rights I may have under
ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. I further acknowledge that
I have been advised, as required by the Older Workers Benefit Protection Act, that: (a)&nbsp;the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed; (b)&nbsp;I should
consult with an attorney prior to executing this Release and Waiver; and (c)&nbsp;if I am age 40 or older at the time of execution of this release, I have 21 days from the date of termination of my employment with the Company in which to consider
this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); and (d)&nbsp;if I am age 40 or older at the time of execution of this release, I have seven days following the execution of this Release and
Waiver to revoke my consent to this Release and Waiver and this Release and Waiver shall not be effective until the seven day revocation period has expired without my having previously revoked this Release and Waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I agree not to disparage the Company and its officers, directors, employees, shareholders and/or agents, in any manner likely to be harmful to
them or their business, business reputations or personal reputations; provided that I may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar
compulsion of law) or as part of a government investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I acknowledge my continuing obligations under my Proprietary Information and
Inventions Agreement. Pursuant to the Proprietary Information and Inventions Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all
Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control. I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the
terms of this Release and Waiver is contingent upon my continued compliance with my Proprietary Information and Inventions Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with
regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of
the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g453477g71b77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453477g71b77.jpg
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M 0$! 0$!_\  $0@ 00#W P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M   *!@<("00%"P$" __$ #T0  $$ @(! P," P0&"P    ,! @0%!@< "!$2
M$Q0)%2$B,0H6%R,D,D$8-U%Q=;0S-#A"5G)VE+.UUO_$ !P! 0 " P$! 0
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M*L(X"K1N1RC>+XD^-7.E#^L7U-D#EQA,W8PVMW(/JI+9F,9;MF50RF28,LB
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MZX\C1]_;\:P= HC8*4NJ$>ON 2P!\=FWWO8]O?\ "K,X?$JY?<&037XXZ8[
MGV<F4^I:Q*P(&XLZ)=O'\?\ NZ0S7\@T<"C_ +NLB0#V/T*)4L-_),G02#*%
MS=RQ0H@GWWF8WH>VWS^/N+:JKMOX^*MR\[JOV$<+]>N<6%])%),\A@ [*J+,
MI<:X_"(VNF*+KX>;KQ\:K(Z^W=;U&]*;4XJ6M-6V:UJ$M2&E).%\Z 66_P!
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MRRSL@) + !B-DU9\5@?5]&+8<A%-D$-ZKD'B)6E26V+:!/%HHH5<@$A22 =
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MZ3+T[QF/5OAU+>2C?N=B& _N'J/Z_'SKE?7,[49?I;L'TY@X :I_F74H[W?
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MW#@5]-D#([$+:%5U\ZYQ(O<7ZZ-=W&.W(2!Y:U;0G7_V]+-L_95)->6-<]Z
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ME:\CEFUOLAY JS$?,1.5<_@IK[U%)<Q=:6LMG'WKB-+22*'>N\41V:('Y&5
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B4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g453477g71e42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453477g71e42.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &3 EX# 1$
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ML? '-#56=(&SP2-"<G.5M-35,Z*CLN$V8G7Q)$-$@H/#_]H # ,!  (1 Q$
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MB8)H(T8DY (D0G_<HDYXO]#>9GG\:=\8N'34P+>-1A-!SH'42#<<7?-XZ[9
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M@Y+JENX!+2H,_/@&DRF@@4>;A7@@8%K? :]Q<2039K2@K9<QP#KME0LN+@2
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ML22R(S9"P*T#Q2E*6 !3:VIJ[A',M=;5@&RGO)>>2UK"WC-=W#R0\PB$-,4
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M((X)9.G>:2:*6;EQ?"ZR^2:22>2N>=\$\,;VQM>'/RJPN71$HB41*(JE\@M
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MO'Z-U&-,B9*WU]%LI.$4LN.DRPADH>1=9.B1!R[[9=9LOV2_+&"9PEG:^.)
MZ\4-.\%2>*3I,B^3W0NER61E0CK&&$%CY)R8*N'P-D\<KE7DF$S1V02=.$U'
M#)VXF  #*EEF*C;-21 PQK*]R(I@Y;DJ=U?)[H#2A!&[9[K&'N&^6$C3NWS$
M-^L63E^<QSE*6*.-L4\4I#EL*==MTL<;)O\ &7R+!QCG@6>XJD6/0XT\?VV+
MK!#3NOD4WRF:CY).-#<4G_7&X9G=)\E9'K;UO@SCP-FBU=8JMD&8MDU023;H
MXIT2IW5,XWJ[7D0(IEXS#P88HBS)CT'[-IC@Z09&R2)@PW06ROGDBF5*-VY
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M$0S72Q9XI+-1;)NJEB.9.!H_%-1%##/#%B.>.V#.V-[6;,G3AJCU""ZJ>4T
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M5[*3Z EA6'/+@"R@.4[0N%W+6IW*#*2:"AS& $B)4C(T"_*;ZUI2S3(2ZIO
M J4%F6U"\D(0XL)F&$<)B980%;/,Q%&.EP#Y0FLS A5!3@,@&(.F+9N^*M'3
MT$W9W8N(\,=J2AXD2-%C7.)I1U*$VB*$&MPI2EPJ:TR4%YJ3+FL #@6U! +
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MNP/MY&^'.#22X<"UP?6'@ K1@3XYE*&VE]:-HI'(+W-6=PR)+"U8_%2A8Z8
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M/^!3"]P((J""-T&H0@M-' @[A!!YBOIF?!)O7@U0T)P(CK",B##,DSQ>L<9
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M[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P4UKX
MX,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6P!^^3
M'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P4UKX
M X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6P!^^
M3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P4UK
MX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6P!^
M^3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P4U
MKX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6P!
M^^3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P4
MUKX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6P
M!^^3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?P
M4UKX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/6
MP!^^3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)?
MP4UKX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?/
M6P!^^3'[RIKTT4<,3'0E_!36O@#@R!THOB)WJO'SUL ?ODQ^\J:]-%'#$QT)
M?P4UKX X,@=*+XB=ZKQ\]; '[Y,?O*FO311PQ,="7\%-:^ .#('2B^(G>J\?
M/6P!^^3'[RIKTT4<,3'0E_!36O@#@R!THOB*6QC2&J899[C&(6-#V(W;W>V;
M+$,NR+M;+6;WSZ^\5Z76K.%NIZGJ?^9ET^GYW2P)W1!AG"6+,]/Q9C$V\5;;
M"%C&6;=+$-OG6&UK7S0LR5P-@N1QFE9.'!QMG&62\VK%JS6T\Y+3LE,MZE7<
M/%/25M_?<?/5@:=FM^=S-S++TK+[TWMSIW#Q3TE;?WW'SU-.S6_.YFYDTK+[
MTWMSIW#Q3TE;?WW'SU-.S6_.YFYDTK+[TWMSIW#Q3TE;?WW'SU-.S6_.YFYD
MTK+[TWMSIW#Q3TE;?WW'SU-.S6_.YFYDTK+[TWMSIW#Q3TE;?WW'SU-.S6_.
MYFYDTK+[TWMSIW#Q3TE;?WW'SU-.S6_.YFYDTK+[TWMSIW#Q3TE;?WW'SU-.
MS6_.YFYDTK+[TWMSK.CQK$4WLT'M\&K>V>2EDL+YWQZO/I=5ET\\LLNG?I6Z
M?G]*K$2(^*ZW$<7.H!4TR#)DHKS&,AMLL%EN6@X^5<ZJ%4E$2B)1$HB41*(E
M$7"(,&Y-HNS<VRM@N@X0ZZG>V"Z%G+=5JHJW5OCE=%;K*ZN&*EK7O:V>6-[9
M8Y98WKAO=#>U[<K7--#>UUEP< X75;5H-.('* 5;BPVQ6.ANK1S7-J+G-M-<
MPEIOLNLN(!XR,A(76.VX%;*UU+,C^D-WYQYKFI;I)F6CQL^Q:6SZJS$GVLLZ
M$R-O;[N:;T6S:JW\[-G;_BOZ0[1S@["$J(&&L"-F'AIV4%S"RU2EN%C+,67=
MQLBN<,H<O*6_)WA3!DYIG &'S*L+O-CLB->&5KBXIA6X,TVX5$2"QKMMJOY$
M=6QF(RJ83IHBHO+IYB$M)BRW6+7<=HQZ;%#!LBV;-4&V"^6&;QYUI'"[IUG;
M-2UL$4$TN$FL)3,U*RDD\ALI(F-I:$*[''Q"]Q<YSG.<0*,;4FRT4&4U]&D\
M$RLG.3N$&-+IW".(TU&=9JX2\,0V!K6M8UH=0O?1HM/-]S6ANR.E;[G2MTON
M_<__ .]&]:];2E<J_G)/#.U[988WME;+&_3M;S[9?\5NG]WS_.Z?_P!;6O\
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M*(E$2B)1$HB41*(E$2B)1$HB41*(E$5J>)?W\2+^RBO^KBJX;1[]%RGV]O\
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MZ\D@1S-IM&-D8R-P*.12,9K=K1T1DL;C,D+F 1GM+*<!H521W-D5AX(@HWC
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MG36_"]:F/\N9.[AUZ6C_ .ZI^W37!%]5E_\ -G36_"]:F/\ +F3NX=>EH_\
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MBY44Q:K&%W399' 0DMF2ZK'&]VML5$[YQ8?2MEVV<AR"\FF6G'DXU-IH-"X
M\NV<@Y>+*LX/)C2R&3H408DVV*RS;)P/=H/$,7#92Z3A#)9LHHG99!7')-9*
M^75I*6OAGCCE:]J@@C*"-N^[+D4@@Y"#M7&M^XN=4*4HBV5K[_@*_P#N9?\
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M-,FJ2KI?J\K77?.T![!H@DE@HNZ>D"#IJ/'L6J2SM^_=-F;1%9RNDEG(!<:
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MP44LB*341HTQ:;9,)GF1!6@% ]UNK10 6:.# -HD#+0U"!0U$5USF&EYO8+
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MZ9ELZ?I(DR)S-TA+A@+M(0.DI=E^+J>_X-RP3/HBDO2800H;TN0393!&3/)
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MG=33<KZS+]=#[R=JBGI:_P#>;CYNFE)KU:8ZF)W4TW*^LR_70^\G:HIZ6O\
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/&;!PUI>2!=NJ0T#(%__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
